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ABSTRACT
ENGINEERED PROTEINS AS TOOLS TO UNDERSTAND
UBIQUITIN SIGNALING
SEPTEMBER 2020
LIN HUI CHANG, B. S., UNIVERSITY OF TOKYO
M.S., UNIVERSITY OF WISCONSIN-MADISON
PH. D., UNIVERSITY OF MASSACHUSETTS AMHERST

Directed by Professor Eric R. Strieter

Ubiquitin is a 76 amino acids protein that is evolutionary conserved in
eukaryotes. It is an important signaling molecule in a plethora biological events,
such as protein degradation, DNA damage response, and transcription. This
thesis aims to develop engineered protein as a tool to study ubiquitin signaling.
Through targeted mutagenesis and directed evolution, a deubiquitinase is
reprogrammed into a transamidase, which lead to the generation of ubiquitinprotein conjugates with discrete ubiquitin linkages through auto-ubiquitination.
These ubiquitin-protein conjugates could be used as a model substrate to profile
their interaction of different ubiquitin interacting proteins. In addition, using
directed evolution and deep sequencing, a nanobody-based binder targeting a
deubiquitinase is engineered. This nanobody could be utilized as an intracellular
probe to study the regulation of the deubiquitinase with great spatial and
temporal control.
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CHAPTER 1
INTRODUCTION
Ubiquitination machinery
In the late 1970s, a heat-stable protein, named as ATP-dependent
proteolysis factor 1 (APF-1) was elucidated to play a crucial role in the ATPdependent proteolysis; it is further demonstrated that single or multiple APF-1s
are conjugated to the substrate to activate the proteolysis of the substrate. 1,2,3
APF-1 is later shown to be ubiquitin and the discovery of the ubiquitin dependent
proteolysis has been awarded with 2004 Nobel Prize in Chemistry. 4
Ubiquitin is a 76 amino acids protein and is evolutionally conserved in
eukaryotes. Since the discovery of the role of ubiquitin as the signaling molecule
in proteolysis, ubiquitin has been shown to be involve in a plethora of biological
events. This process, known as ubiquitination, is achieved through the formation
of isopeptide or peptide bond between the C terminal of ubiquitin with the αamino group of the N terminus or ε-amino group of the lysine of the substrate.
This conjugation is an ATP dependent enzymatic cascade involving ubiquitin
activating enzyme (E1), ubiquitin conjugating enzyme (E2) and ubiquitin ligase
(E3).5 These enzymes are referred as the ubiquitin writers. Their actions are
reversible, and the removal of ubiquitin, or the ubiquitin editing are performed by
deubiquitinase (Figure 1-1).6
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Figure 1-1: Ubiquitination machinery

In addition, ubiquitin contains eight residues with primary amines; other
than the α-amino group on the Met1, ubiquitin has seven lysine which are Lys6,
Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63 (Figure 1-2A). Hence, a single
ubiquitin can be further connected to another ubiquitin at these residues to form
different polyubiquitin. Here, the lysine donating moiety is referred as the
proximal ubiquitin and the lysine accepting molecule is the distal ubiquitin. Here,
homotypic chain describes the ubiquitin chain which is formed from the
conjugation at the same lysine, while the heterotypic chain refers to the ubiquitin
chain containing different linkages. Especially for heterotypic chain, it could be
further categorized into mixed and branched polyubiquitin (Figure 1-2B). It has
been reported that all kind of ubiquitin linkages present in cellulo, although 60%
of the total cellular ubiquitin is estimated to be in the form of monoubiquitination
compare to 11% for ubiquitin chain.7,8,9,10
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Figure 1-2: Ubiquitin and its conjugates
(A) Crystal structure of ubiquitin (PDB ID: 1UBQ). The Met1 and its seven lysine
residues are highlighted in color. (B) Examples of ubiquitin conjugates.

How are different ubiquitin conjugates recognized by their interacting proteins?
Different ubiquitin conjugates have been reported to elicit distinct cellular
responses. For example, mono-ubiquitinated histone has been associated with
transcriptional regulation, Lys48 linked ubiquitinated substrates are subjected to
proteasomal degradation and Lys63 linked ubiquitin conjugates are reported to
participate in DNA damage response and NF-ᴋB signaling pathway. 11,12,13,14 This
prompts a perception that the different ubiquitin conjugates adopt different
topologies and hence, are recognized by certain ubiquitin interacting proteins,
such as the deubiquitinases or ubiquitin binding domains (also referred as the
readers).
Extensive structural and biochemical studies have demonstrated that
ubiquitin conjugates use distinct surface regions to interact with their interacting
3

proteins. The main interaction surfaces of ubiquitin are at the hydrophobic
surfaces center at Phe4, Ile36 and Ile44 of the ubiquitin. 15,16 In addition, the C
terminal of ubiquitin which is involved in conjugation is another important
interacting surfaces. For example, the zinc finger ubiquitin binding domain (ZnF
UBP) of USP5 develops a deep binding cleft to recognize the C terminal GlyGly
motif of ubiquitin.17 The conformation of ubiquitin chain with different linkages are
determined by these surfaces too. Majority of the Lys48 linked ubiquitin dimer
adopts a ‘closed’ conformation and interacts through the Ile44 patches; the UBA2
domain of the hHR23A, which is a proteasomal shuttling factor is shown to
sandwiched between the Lys48 linked ubiquitin dimer and interact with both
ubiquitin moieties at the same hydrophobic surface. 18
Amounting evidence has suggested that the activities of deubiquitinases
are influenced by the substrate which is ubiquitinated too. While the catalytic
domains of these deubiquitinases are responsible to recognize ubiquitin, the
specificity of the deubiquitinases are benefited from the interaction between the
external domains with the substrate. USP7 is reported to recruit substrates by its
N terminal TRAF domain and preferentially remove ubiquitin chains en bloc from
its targets, such as p53 and PCNA, but not breaking down the ubiquitin
chains.19,20 These studies have underscored that other than the ubiquitin
linkages, it is crucial to investigate the substrate in order to understand the
interactions of ubiquitin conjugates with their editors or readers. This is nontrivial, as it remains a great challenge to produce defined ubiquitin protein
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conjugates. Numerous efforts have been devoted to innovating the generation of
ubiquitin protein conjugates.

How the specificities of ubiquitin interacting protein are regulated?
Ubiquitin conjugates involve in various signaling pathways inside the cell,
and aberrant interactions of the ubiquitin conjugates with their interacting
proteins, such as the deubiquitinases and ubiquitin binding domains, are
detrimental. In fact, anomalous activities of these ubiquitin interacting proteins
had been elucidated to lead to numerous diseases such as cancer and
neurological diseases. The overexpression of RPN13, which is a proteasomal
ubiquitin receptor has a poor prognosis in ovarian cancer; 21 and a E7A mutation
of UCHL1, which is a deubiquitinase, has reported to have reduced activity, and
the loss of function leads to an early-onset progressive neurodegenerative
syndrome.22 Hence, understanding how the ubiquitin interacting proteins are
regulated could give insight into the development of novel therapeutic
intervention. Generally, these deubiquitinases and ubiquitin binding domains are
regulated at their expression or abundance level, post translational modification,
and recruitment to macromolecular complexes.

Regulation of the proteasome associated ubiquitin receptors and deubiquitinases
Here, we would use 26S proteasome as an example to explain the
regulation of ubiquitin editor and readers that are involved in the ubiquitin
proteasome system. 26S Proteasome is a 2.6 MDa complex consists of around
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30 subunits. These proteasome subunits are categorized into 20S CP (core
particle), which consists of all the subunits in the proteolytic chamber and 19S
RP (regulatory particle, also known as PA700), containing the ATPases and
non-ATPase regulatory units, including the proteasomal ubiquitin receptors,
RPN10 and RPN13 and proteasomal deubiquitinases, RPN11, UCH37 and
USP14 (Figure 1-3A). 23 As the main protein degradation machinery in
eukaryotes, proteasome degrades the protein through the ubiquitin proteasome
system (UPS). In this system, the proteasome is recruited to the ubiquitinated
substrate through its ubiquitin receptors. The proteasome associated
deubiquitinases will break down the ubiquitin chain or remove the ubiquitin from
the substrate. This is followed by the unfolding of substrate by the AAA+
ATPases. In addition to the unfolding, the ATPases also trigger the opening of a
gated access channel and facilitate the translocation of the substrate into the
peptidase chamber for proteolysis (Figure 1-3B).24 Proteasome has been a
promising therapeutic target in oncology therapeutic. Bortezomib, under the
brand name Velcade®, which inhibit the peptidases, had been approved FDA to
treat patients with multiple myeloma with patients achieve complete remission. 25
Currently, proteasome associated ubiquitin interacting proteins also gain great
interest as a pharmacological target due to their well-developed binding pockets.
Numerous studies are now underway to study their role in cellular physiology.
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Figure 1-3: Proteasome
(A) Representative cryo-EM structure of proteasome (PDB ID: 5A5B) with
proteasome associated deubiquitinases and ubiquitin readers being highlighted
in color. (B) Ubiquitin-proteasome system.

Expression level
Expression of the proteasome subunits are subjected to dynamic
regulation to maintain protein homeostasis.26,27 In steady state, the basal
expression proteasome subunits are controlled by the transcription factor NF-Y
through the consensus sequence at the promoter regions. 28 Nonetheless, it has
demonstrated that certain proteasome subunits are overexpressed in solid
tumors; they are RPN1 and RPN13, which are the proteasomal subunits
recognizing linear and branched Lys48 linked ubiquitin chains. 29,30 On the other
hand, it has been elucidated that while the challenge with proteasome inhibitors,
such as bortezomib or carfilzomib, would increase the transcription level of most
proteasome subunits by the transcription factor Nrf1, the reduction of 19S RP
subunits, including RPN11 and RPN13 would convey resistance to those
proteasome inhibitors across a broad spectrum of cancer cell lines. 31,32,33 These
findings highlight the importance to investigate the differential expression levels
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of the proteasome associated ubiquitin receptors and deubiquitinases in the
development of effective therapeutics targeting the ubiquitin proteasome system.

Post translational modification
In addition, the proteasome associated ubiquitin readers and
deubiquitinases could be regulated through post translational modifications, such
as phosphorylation and ubiquitination. These modifications on these subunits
influence the activity of proteasome either (i) by modulating their catalytic
activities or (ii) by interacting differently with the macromolecule complex or with
ubiquitin conjugates. For example, the catalytic activity of USP14 changes upon
post translational modification. USP14 is shown to be phosphorylated at Ser432
by Akt and it is speculated that the negatively charged phosphate group induces
a rearrangement of the autoinhibitory BL2 loop of USP14, hence, activates its
deubiquitinating activity in vitro and in vivo. It was further demonstrated that
USP14 KO cells with exogenous USP14 containing phosphomimetic mutations
has decreased global proteasomal degradation.34
Post translational modification could positively and negatively regulates
the interactions of the proteasomal subunits with proteasome. hHR23B, which is
a proteasomal shuttling factor that transports ubiquitinated substrate to
proteasome, could be phosphorylated at its UBL domain, which is the domain
that bind to UBL receptors of proteasome. While this phosphorylation weakens
the interaction between hHR23B and proteasome in Saccharomyces cerevisiae,
the role of the phosphorylation of hHR23B in mammalian cells is yet to be
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studied.35 There are examples where phosphorylation events would improve the
binding with the proteasome. The phosphorylated RPN2, which is a proteasome
scaffolding protein at Tyr950 has a higher binding affinity towards RPN13 in
vitro.36
On the other hand, ubiquitination of the proteasome associated subunits
has been reported to modify their interactions with the ubiquitin conjugates. In
yeast, RPN10 is shown to be monoubiquitinated. It was demonstrated that
RPN10 mutant which could not be ubiquitinated could not complement the rad23
and rpn10 null yeast cell, suggesting a possible role of the monoubiquitination
species in important for normal cellular physiology. Nonetheless, the
monoubiquitinated RPN10 shows lower binding affinity towards ubiquitin chains,
possibly via the inhibition at the ubiquitin interacting motif (UIM) of RPN10; this
has resulted in the lower rescue efficiency in the yeast with defective proteasome
lacking RPN10 and RAD23.37 In addition, RPN13 is significantly
autoubiquitinated upon proteotoxic insult. In vitro, ubiquitination of RPN13 inhibits
its binding affinity of proteasome towards ubiquitinated substrate, and hence
decrease the capacity of proteasome to degrade the substrate. Although the
functional consequences of the autoubiquitinated RPN13 in a cellular context
remains to be elusive, it is suggested this modification could involve in a negative
feedback loop during proteotoxic stress.38
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Recruitment to proteasome
Proteasome itself is a dynamic macromolecule complex; in general, the
association between 19S RP and 20S CP to assembly the 26S proteasome is
labile and sensitive to the environment. Under oxidative stress, the 19S RP
would dissociate to facilitate the degradation of the oxidized protein by 20S CP in
an ATP and ubiquitin independent pathway. 39,40 In an inflammatory response, the
cytokines such as TNF-α and IFN-γ trigger the swapping of the β1, β2 and β5
subunits of 20S CP to β1i, β2i and β5i subunits. The 26S proteasome would also
disassemble with the 20S CP assemblies with other activators such as PA28αβ
to generate immunoproteasome.26
Interestingly, little is known about the assembly and the dynamics of the
19S RP, although studies have elucidated that the several components of 19S
RP are dynamic interactors of the 19S RP. A quantitative cross-linking mass
spectrometry has demonstrated for the purified proteasome, the RPN13 and
UCH37, which is recruited to proteasome through RPN13, are at substoichiometry level in various mammalian cell lines. The same observation is for
USP14.41,42 It was further shown that these interactions are dynamic, and these
proteasome associated subunits are readily swapped between the proteasome
bound and free state.43 These observations are interesting as it has been
suggested that these deubiquitinases may have difference ubiquitin editing
preferences: UCH37 preferentially hydrolyzes Lys48 linked branched ubiquitin
chain, while USP14 removes ubiquitin chain en bloc.44,45 This is in contrast to the
RPN11, which is the constitutive proteasome associated deubiquitinase that
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remove the ubiquitin chain en bloc by hydrolyzing the isopeptide linkage between
the proximal ubiquitin and substrate upon the translocation of substrate into the
20S CP.46 Hence, it leads to the hypothesis that proteasome with different
composition of deubiquitinases may have different deubiquitination pattern.
In addition, both USP14 and UCH37 are suggested to regulate
proteasome activity towards distinct substrates. 47,48 Through in vitro
complementation test, proteasome with WT USP14 shows decreased
degradation compared to proteasome with catalytically inactive USP14; while
proteasome depleted of both USP14 and UCH37 also has lower degradation
efficiency compare to proteasome lack of USP14 only. 49,44 This lead to the
speculation that the dynamic recruitment of USP14 and UCH37 to the
proteasome might generate proteasome with different degradation capacity in a
cellular context. The question is, what is the trigger of the (dis)incorporation of
these deubiquitinases? What are the functional consequences of a proteasome
lack of USP14 or/and UCH37? Advanced intracellular probes for these ubiquitin
readers or editors should be developed to monitor their interactions with
proteasome spatially and temporally.
In short, findings suggest that these proteasome-associated ubiquitin
readers and editors play a crucial role in determining the ubiquitin dependent
proteasomal degradation. Hence, they are under dynamic regulations at multilevel, possibly to fine tune the proteasome degradation capacity under different
cellular conditions to promote cellular survival.
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Protein engineering in ubiquitin system
In the previous section, we highlighted two emerging questions in the
study of ubiquitin signaling: (i) the generation of defined ubiquitin protein
conjugates to understand their interactions with the ubiquitin editors or readers
and (ii) the generation of intracellular probe for ubiquitin interacting proteins. In
this thesis, we would like to tackle the questions through protein engineering.
Protein engineering describes the process to develop proteins or enzymes with
desirable functions and has been widely applied in both academic and industrial,
and the methodologies and techniques developed in protein engineering are
awarded with 2018 Nobel Prize in Chemistry. The research in the ubiquitin field
also benefited from protein engineering, and numerous next generation probes
targeting the ubiquitin system has been engineered. 50

Rational design and directed evolution
The two mains methodologies in protein engineering are rational design
and directed evolution. In rational design, prior knowledge, such as the structure,
sequence alignment, and function or mechanism of a protein or its homologs, is
critical to guide the engineer of a protein. The precise amino acids of the
engineered protein are mutated based on site-directed mutagenesis, and the
mutants are characterized to determine whether they carry the desired
properties. Rational design has deepened our understanding about the role of
amino acids in determining the binding and catalysis of a protein while laying out
the foundation for the computational design of de novo protein. Nonetheless,
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rational design requires a tedious characterization of protein mutants and limit
the number of mutants to be tested. Also, it could be impractical if nothing is
known about the protein to be designed.51
On the other hand, directed evolution could circumvent the lack of
knowledge of the structure and function of the protein. The booming of the
directed evolution is benefited from the advances in gene diversification, high
throughput screening methods through various display technologies, and deep
sequencing. In principle, the protein of interest is subjected to mutagenesis,
either through targeted or random mutagenesis, to generate an ensemble of
mutants. This ensemble, also referred as library, is challenged with an artificial
selection and screening to enrich for the mutants with improved function, while
the mutants with poor outcome are discarded (Figure 1-4).52 The power of
directed evolution is that a library with large amount of mutants, with 10 6 – 1013
could be generated in the laboratory which would be selected or screened in a
high throughput fashion, and the enriched mutants could be further identified
through next generation sequencing to give insight into the beneficial mutations
at amino acid level.
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Figure 1-4: Directed evolution
Scheme of directed evolution exemplified by yeast surface display.

While the traditional way to generate a library is through error prone PCR
reaction to introduce random mutation on the gene of interest, the improvement
in synthesis of DNA oligos has further expanded the protein sequence space. For
example, DNA oligos with degenerate codons allow saturation mutagenesis at
certain regions of the protein. In addition, homologous recombination, such as
DNA shuffling, permits the combination of enriched gene which may yield a
synergistic effect.53
Various display methods have been developed to facilitate the directed
evolution of a protein. These display methods linked the genotype of a to-bedesigned protein with its phenotype to enable the identification of the isolated
clones through the high throughput selection or screening strategies. The
proteins could be (i) displayed on the surface of phage, bacterial, yeast and
14

mammalian cells, (ii) fused to molecules such as ribosome or mRNA.54,55,56,57,58,59
Recently, microfluidics technology has been applied in the in vitro
compartmentalization of gene of interest together with a transcription and
translational machinery, providing an alternative to establish the phenotypegenotype linkage necessary for directed evolution. 60 These different methods,
which determine the size of the library and the suitable selection and screening
strategies have their pros and cons. For example, the transformation efficiency of
yeast surface display has limited the size of library to be 10 7 – 109, which are
smaller compare to size of library generated by phage display at the order of
1010. Nonetheless, yeast surface display could be coupled with fluorescent
activated cell sorting (FACS) with outstanding advantages: each clone could be
scrutinized in FACS, hence it is efficient for positive and negative screenings,
and the multicolor capabilities of FACS enable the quantitative control through
normalization of display level.61
In addition, the application of next generation sequencing has
revolutionized the directed evolution of protein, especially in the engineering of a
protein binder. The increased sampling depth, which is in the order of 10 6 and
the quantitative assessment of the isolated clones offered by the high throughput
sequencing platform have led to the discovery of binders with improved binding
kinetics.62 In addition, next generation sequencing is capable to detect clones
with marginal improvement in binding; these small beneficial mutations could be
synergistic and essential to overcome the “fitness valley” in the protein
engineering landscape.63

15

Engineered protein as tools to study ubiquitin system
Despite their differences, rational design and directed evolution are
complementary. Many research labs, including in the ubiquitin field have
combined both techniques to generate engineered protein as tools to study the
ubiquitin system. For example, E3 ligases have been engineered to catalyze the
generation of certain conjugate. Here, a modular human E3 ligase, CHIP
(carboxyl terminus of Hsc70-interacting protein) is reprogrammed to recruit
specific substrate to the E3 ligase to induce the ubiquitination of the substrates.
The recruitment is achieved by fusing the CHIP to a substrate specific singlechain variable fragment (scFv) or a fibronectin type III domain monobody. It was
further demonstrated that the engineered CHIP could be expressed intracellularly
to ubiquitinate and to further degrade the targeted substrate. 64 This study
revealed that the induced ubiquitination through proximity effect by a modular
ubiquitin ligase is possible. Nonetheless, study has shown this strategy yield a
mixture of ubiquitin protein conjugate with ubiquitin chain of different length and
linkages. It remains a great challenge to prepare ubiquitin protein conjugate with
distinct ubiquitin chain architecture.
Different engineered proteins have been developed to facilitate the study
of ubiquitin chains. The K11/K48-bispecific antibody targeting heterotypic Lys11and Lys48 linked ubiquitin chain is designed by the knobs-into-holes technology
to heterodimerize the monospecific Lys11 or Lys48 antibodies. The antibody,
which displays higher binding affinity towards heterotypic chain than the
homotypic K11- or K48 linked polyubiquitin, had been applied successfully in
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Western blot, immunoprecipitation and immunofluorescence. 65 In addition,
affimers targeting Lys6 linked and Lys33 linked ubiquitin chain has been
engineered. Affimer is a synthetic binding protein and the linkage specific
affimers have given insight into the distinct conformation of the ubiquitin
linkages.66
Other than being the tools to recognize ubiquitin conjugates, engineered
proteins targeting the deubiquitinases and ubiquitin readers had been designed.
By using ubiquitin as scaffold and phage display, the Sidhu’s lab generated
different ubiquitin variants (UbV) targeting proteins in the ubiquitin system, for
example E2 and E3 ubiquitinating enzyme, deubiquitinases from the USP
families, and ubiquitin binding domain like ubiquitin interacting motif (UIM).
Structural studies elucidated that all the ubiquitin variants target the same active
site or binding site as the wildtype ubiquitin. Hence, these ubiquitin variants could
be used as the intracellular probes which modulate the activities, either inhibition
or activation, of their targets.67,68 These findings also indicated that due to the
structurally conserved ubiquitin binding site shared by the ubiquitin writers,
editors, and readers, it is inevitable that the ubiquitin derived protein would
occupy the same site. Nonetheless, since different ubiquitin binding sites have
low sequence consensus, it is possible to fine tune the specificity of the ubiquitin
variants by exploiting the interactions of ubiquitin variants with the non-conserved
sequences.
Ubiquitin variants which bind the ubiquitin binding sites are ideal to be
developed as the probes which modulate the activities of their target.
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Nonetheless, applications such as intracellular imaging require the probe to have
minimal perturbation on the target, which is inapplicable for ubiquitin variants. On
the other hand, there are examples of protein binders with non-ubiquitin scaffold
targeting the ubiquitin readers. DARPin (designed ankyrin-repeat proteins)
targeting the CC2-LZ domain of NEMO has been designed through ribosome
display. NEMO is a regulatory component in the NF-ᴋB signaling. It dimerizes to
bind to linear ubiquitin chain and both dimerization and ubiquitin interactions
involve the CC2-LZ domain. Here, this DARPin was utilized as a chaperon to
assist the crystallization of the dimeric CC2-LZ domain and as an intracellular
inhibitor of the NF-ᴋB signaling.69,70 Crystal structure suggested the DARPin also
interacts with the NEMO at the same interaction surfaces as ubiquitin as well.
This is not surprising, as the binding site for the substrate, that is the ubiquitin, is
a well evolved binding cleft.
In short, engineered proteins have play an active role in helping the
scientific community in understanding the ubiquitin system. The well-developed
methodologies and techniques in protein engineering have facilitated the
generation of tools to study the ubiquitin signaling.

Forward to thesis
Studies have shown that substrates with different ubiquitin topologies and
chain lengths would have different biological outcomes. Nonetheless, the major
challenge in understanding the interactions of the ubiquitin conjugates and their
interacting proteins is to generate ubiquitin protein conjugates with defined
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ubiquitin linkages. Chapter 2 describes a facile method to generate a
ubiquitinated protein which is ubiquitinated site specifically with distinct ubiquitin
chain. This is achieved through the reprogramming of a deubiquitinase, Yuh1,
into an auto-ubiquitinating ligase through a combination of targeted mutagenesis
and yeast surface display for directed evolution. We further demonstrated that
this ubiquitin protein conjugate could be a model substrate to profile DUBs
activities.
On the other hand, understanding how the ubiquitin editors or readers are
regulated are crucial to obtain a complete picture of the ubiquitin system. Here,
small protein binders are a powerful tool to study target protein in vitro, in cellulo,
and in vivo. In chapter 3, we describe the generation of a nanobody with high
binding affinity towards a proteasome-associated deubiquitinase, UCH37,
through directed evolution using yeast surface display. We further confirmed the
interaction of the nanobody with proteasome-associated UCH37 in a cellular
context. This suggests the nanobody could be developed as the intracellular
probe for proteasomal UCH37.
As one of the proteasome-associated deubiquitinase, UCH37 is
responsible to specifically hydrolyze the Lys48 linked branched ubiquitin chains.
It was shown that UCH37 interacts with proteasome in a dynamic fashion. What
is the physiological relevance of the transient interaction of the UCH37 with the
proteasome? We proposed to use the nanobody specific towards proteasome
associated UCH37 as an intracellular imaging probe to investigate the
recruitment of UCH37 to proteasome. In Chapter 4, we first established that the
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discovered nanobody does not interfere with the catalytic activities of the
proteasome-associated UCH37 and could be developed as a probe for live-cell
imaging.
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CHAPTER 2
REPROGRAMMING A DEUBIQUITINASE INTO A TRANSAMIDASE
This chapter has been published:
Chang, L. H. & Strieter, E. R. Reprogramming a Deubiquitinase into a
Transamidase. ACS Chem. Biol. 13, 2808–2818 (2018).1

Abstract
Investigating how the different ubiquitin topologies interacting with ubiquitin
interacting proteins is crucial to understand the ubiquitin signaling pathway. The
main challenge is the accessibility of the ubiquitin conjugates with well-defined
ubiquitin chains. Here, we report the engineering of a deubiquitinase, Yuh1 which
is capable of auto-ubiquitinating itself site specifically to yield ubiquitin protein
conjugate. Through alanine scanning at targeted surfaces followed by random
mutagenesis and yeast display-based directed evolution, we have discovered a
Yuh1 variant with the transamidation to hydrolysis ratio 28-fold higher than the
WT. This enable the robust autoubiquitination of the Yuh1 variant to install
distinct ubiquitin chains containing the native isopeptide bond on itself effectively.
Further studies using this ubiquitin protein conjugate as the model substrate for
deubiquitinases elucidate that certain deubiquitinases activities are affected by
the substrates linked to the ubiquitin chains. This emphasizes the importance of
interrogation of the ubiquitin protein conjugates in order to fully understand the
biological functions of deubiquitinases.
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Introduction
Ubiquitination is a post translational modification describing the covalent
attachment of ubiquitin moieties onto a substrate through isopeptide or peptide
bond. This process is ATP dependent and is catalyzed by an enzymatic cascade
involving E1 activating enzymes, E2 conjugating enzymes and E3 ligase
enzymes.2,3 Other than the mono-ubiquitinated substrate, ubiquitin contains
amino acids with primary amine, this indicates that ubiquitin can be further
ubiquitinated. Together with Met1 and 7 lysines (Lys6, Lys11, Lys27, Lys29,
Lys33, Lys48, and Lys63) residues, additional ubiquitin molecules can be
attached onto ubiquitin at these primary amines, leading to the generation of
polyubiquitin with different linkages. In the circumstances where the same Lys is
utilized in the chain elongation, the polyubiquitin is known as homotypic chain;
while ubiquitin conjugates containing different linkages are known as heterotypic
polyubiquitin. The architectures of these ubiquitin chains are determined by the
ubiquitination sites. Studies have shown that these ubiquitin moieties in distinct
ubiquitin chains interact differently intramolecularly, hence adopting different
conformations.4,5 This ubiquitination process is reversible and an enzyme,
deubiquitinases (DUBs) can remove the ubiquitin modification from the
substrates by hydrolyzing the isopeptide bonds.6,7
These ubiquitin conjugates regulate a plethora of biological processes in
eukaryotes. It has been elucidated that different ubiquitin conjugates trigger
distinct biological events. For example, mono-ubiquitinated histone has been
associated with transcriptional regulation, 8 Lys48 linked ubiquitinated substrates
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are subjected to proteasomal degradation and Lys63 linked ubiquitin protein
conjugates are reported to participate in DNA damage response. 9,10 The cellular
ubiquitin can exist in the form of unanchored ubiquitin or ubiquitin chains. These
free ubiquitin molecules can be generated from (i) the transcription and
translation of the ubiquitin gene, (ii) the hydrolyzing product of the ubiquitin
conjugates by the DUBs and (iii) the synthesis of unanchored polyubiquitin by
certain ubiquitinating enzymes. It has been established that these unanchored
polyubiquitins also involve in biological processes. For example, Lys63 linked
ubiquitin chains involve in the activation of protein kinases in the NF-ᴋB signaling
pathway.11 Furthermore, quantitative analysis has shown that the percentage of
the distinct ubiquitin conjugates vary depends on the cellular states, such as
during cell cycles and cellular differentiation.12
This project is motivated from our goal to understand how ubiquitin editors
and readers recognize these defined ubiquitin conjugates (Figure 2-1). To
facilitate these studies, enzymatic and chemical methods have been developed
to generate ubiquitin activity-based probe, ubiquitin-peptide or protein conjugates
(also known as anchored ubiquitin), and unanchored ubiquitin chains. These
ubiquitin conjugates have provided valuable insights into the biochemical and
biophysical characterizations of the ubiquitin interacting proteins.
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Figure 2-1: The possible topologies of ubiquitin conjugates in cellulo

Despite the advances in the synthesis methods of ubiquitin conjugates,
there are limitations with the current techniques. Enzymatic protocol using
ubiquitinating enzymes has been widely used to prepare unanchored ubiquitin
chains.13 Nonetheless, the generation of ubiquitin protein conjugates remains
challenging and problematic; these ubiquitin protein conjugates tend to be
decorated with heterogenous linkages, and the ubiquitination mostly fused to the
N or C terminal of the substrate and are non-site specifically. 14,15,16 While the
chemical method which modified from native chemical ligation has been
successfully applied to prepare ubiquitinated histone site-specifically, the reaction
conditions are harsh.17,18 The necessary denaturing conditions have limited this
protocol to be applicable for robust proteins only, such as histone and ubiquitin.
Here, we question that could we engineer a modular ubiquitin transamidase to
catalyze the transfer of distinct ubiquitin chains on a substrate site specifically to
generate ubiquitin protein conjugates of interest?
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We have discovered a deubiquitinase, Yuh1, has the potential to be
developed as a modular ubiquitin transamidase. Yuh1 is a 26 kDa yeast ubiquitin
C-terminal hydrolase which is reported to hydrolyze the isopeptide or peptide
bond of ubiquitin conjugate to small adducts. Yuh1 shows structural similarities to
papain-like cysteine protease, consisting the catalytic triad at Cys90, His166 and
Asp181. Both His166 and Asp181 act as the general base and acid to protonate
and prepare Cys90 for the nucleophilic attack at the carbonyl carbon of the
scissile bond.19 It is proposed that upon the binding of Yuh1 with its substrate, for
example, ubiquitin with a single Asp extension at its C terminal (UbD77), the
Cys90 would attack the scissile bond, leading to the formation of the acyl enzyme
intermediate. Under normal conditions, the intermediate will be hydrolyzed to
yield the free ubiquitin molecule. Our group has shown that this deacylation step
can be intercepted by nucleophilic amines to attach small amines at the ubiquitin
C terminal (Figure 2-2).20,21 The transamidation is achieved by extreme reaction
conditions; alkaline pH and high concentration of amines are necessary to
generate nucleophilic amines to outcompete the prevalent water molecules, and
the organic solvent, such as 30% DMSO is supplied as addictive to further
reduce the concentration of water to promote the transamidation. Nonetheless,
the problem is that Yuh1 still catalyze hydrolysis with an order of magnitude
faster than transamidation. The activity of Yuh1 is also impeded in high pH. 22
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Figure 2-2: The proposed mechanism of Yuh1 catalyzed hydrolysis and
transamidation

Here, we decided to reprogram the Yuh1 into a modular ubiquitin
transamidase by reducing its hydrolase activity and improving its transamidase
activity under milder conditions concurrently. By using an integrated approach of
alanine scanning, random mutagenesis and yeast surface display based directed
evolution, we have engineered Yuh1 into a ubiquitin transamidase with is
capable of auto-ubiquitinate with distinct ubiquitin chains on a single Lys,
generating ubiquitin-Yuh1 conjugate with a variety of ubiquitin chains. We further
investigated on how different deubiquitinases interact with the ubiquitin-Yuh1
conjugates and elucidated that certain deubiquitinases display markedly different
cleavage activities towards ubiquitin-Yuh1 conjugates and unanchored ubiquitin
chains. Our result demonstrated that ubiquitin-Yuh1 could serve as a model
31

substrate to interrogate ubiquitin interacting proteins and suggested that
deubiquitinases are sensitive to the conjugated substrates.

Result
Targeted mutagenesis
In previous studies, our group has discovered that a deubiquitinase, Yuh1
is capable to catalyze transamidation to append small amines at the C terminus
of mono-ubiquitin or at the proximal ubiquitin of a ubiquitin chains. Nonetheless,
this transamidation requires extreme reaction conditions to overcome the
hydrolysis. First, high pH and high concentration of the amines are required to
generate sufficient nucleophilic amines to outcompete water in the deacylation
process. Second, the presence of organic solvent, such as 30% DMSO are
necessary to further reduce the concentration of water molecules for the
transamidation to occur. The intrinsic hydrolysis activity of Yuh1 is a major hurdle
in our Yuh1 engineering effort. Hence, our initial effort is to improve the
transamidation to hydrolysis ratio of Yuh1.
We decided to perform targeted mutagenesis at the periphery active site
of Yuh1 as we reasoned that these amino acid residues might involve in
influencing the catalytic activity of Yuh1. Based on the crystal structure of a
ubiquitin conjugated at the catalytic Cys of Yuh1, we have identified 3 regions of
interest: (i) the active site- crossover loop (ii) the N terminus of Helix 4 containing
catalytic Cys90 and (iii) the β4-β5 loop containing the catalytic Asp181 (Figure 23). Studies have elucidated that the crossover loop is disordered in the apo Yuh1
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but undergoes a major conformational change upon binding with ubiquitin where
the loop becomes ordered and contacts with the ubiquitin. In addition, the
residues on the N terminus of Helix 4, especially the invariant Asn88, is
suggested to stabilize the active site- crossover loop through hydrogen bond.
Here, we performed alanine scanning on these regions to investigate the effects
of these side chains.

Figure 2-3: Crystal Structure of ubiquitin conjugated at the catalytic Cys of
Yuh1 (PDB: 1CMX)
Yuh1 is covalently attached to the ubiquitin aldehyde (Left) with the catalytic triad
of Yuh1 (Cys90, His166 and Asp181) highlighted (Right).
We expressed the Yuh1 variants in E.coli and we performed the
transamidation reaction using the crude purified Yuh1 variants with UbD77 as
substrate and allylamine as nucleophile. The reactions were carried out under
milder conditions, at pH 8 (contrast to pH 10.5) and for an extended time (Figure
4A). To rapid screen for the transamidation and hydrolysis yield of the Yuh1
variants, we have adopted a matrix-assisted laser desorption/ionization- time of
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flight mass spectrometry (MALDI-TOF MS) assay which was designed originally
to quantify in vitro DUB activity.23 In short, the amount of hydrolysis and
transamidation products were quantitated using

15N-labeled

UbD77 as the

internal standard (Figure 2-4B). Calibration curves for both hydrolysis product,
UbWT and transamidation product, Ub allylamine (UbAA) confirmed the
proportionality of the assay, with the detection capability spanning a range of 10 2104 nM (Figure 2-5A and 5B).

Figure 2-4: MALDI-TOF MS assay
(A) Reaction conditions and the sample preparation for the MALDI-TOF assay to
screen for the transamidation and hydrolysis yield for the Yuh1 variants. (B) An
example of acquired MALDI-TOF MS spectrum. Products were quantified using
the spiked-in 15N-labeled UbD77 as the internal standard.
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Figure 2-5: Calibration curve for MALDI-TOF MS assay
Calibration plot for (A) Ub WT and (B) Ub-allylamine using MALDI-TOF MS. Data
points were obtained from the average measured concentration of 2 technical
replicates from 2 biological replicates. Fitting was performed in OriginPro and
linearity was conserved over 2 orders of magnitude. Red dot represented outlier.

Our result showed that under these reaction conditions, wild type Yuh1
(Yuh1 WT) did not yield any transamidation product, presumably the generated
UbAA was rapidly hydrolyzed into UbWT. However, with a single N88A mutation,
this Yuh1 variant starts to display higher transamidase activity. Among the
alanine mutants, we found that N88A/D162A/L165A (herein referred as Yuh1m)
exhibits the most positive improvement, with a transamidation yield around 30%
and a transamidation to hydrolysis ratio at 3. Both Asp162 and Leu165 are
located near the C terminus of the active-site crossover loop (Figure 2-3). While
alanine substitution of the residues at the β4-β5 have negative effect on the
transamidation activity of Yuh1 N88A, as the transamidation to hydrolysis ratio
has decreased to less than 0.5 compared to Yuh1 N88A. Thus, our result
indicated that alanine mutation of Asn88 and crossover loop significantly improve
the transamidation activity of Yuh1 (Figure 2-6A and 6B).
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Figure 2-6: Transamidation of Yuh1 variants.
(A) Yield of Ub-allylamine (UbAA) and (B) transamidation to hydrolysis ratio of
Yuh1 variants determined through MALDI-TOF MS. Error bars correspond to
standard deviation of two biological replicates and two technical replicates .
To gain insight into the improved transamidation activity of these Yuh1
variants, we performed initial rate measurements, focusing at Yuh1 WT (without
and with the presence of amine), Yuh1 N88A, and Yuh1m. The Michaelis-Menten
kinetics showed that for Yuh1 WT, the catalytic efficiency for hydrolysis under
both circumstances are similar, with 6±3 x 105 M-1s-1 without amine and 8±2 x 105
M-1s-1 with amine, with both Km and kcat are at the same order. This suggested
that the catalytic efficiency for hydrolysis is not affected by the presence of
amines. While the catalytic efficiency for transamidation is 9±1 x10 4 M-1s-1, which
is 10 times lower compare to hydrolysis. The low catalytic efficiency is mainly due
to the decrease in Km (Figure 2-7A and Table 2-1).

36

With the introduction of N88A, we observed a significant decrease in the
rate of catalytic turnover and catalytic efficiencies for both hydrolysis and
transamidation. Especially for hydrolysis, the kcat and catalytic efficiency for Yuh1
N88A is 0.062±0.006 s-1 and 2.3±0.6 x 103 M-1s-1, which are close to two order of
magnitude lower compare to Yuh1 WT. For transamidation, it is close to 10 times
lower compare to Yuh1 WT, at 3±1 x 103 M-1s-1. As a result, the catalytic
efficiency for transamidation is comparable to the catalytic efficiency for
hydrolysis (Figure 7B and Table 1). We detected the similar trend with Yuh1m,
with the similar overall decrease in the rate of catalytic turnover and catalytic
efficiencies, but with the catalytic efficiency for transamidation to hydrolysis at a
ratio of 1.2. Especially the catalytic efficiency of transamidation for Yuh1m is at
6±2 x 103 M-1s-1, which is slightly higher compare to N88A (Figure 7C and Table
1). Together, these data demonstrate that these alanine mutations have
compromised the catalytic activity of Yuh1, renders it an ineffective and yet
promiscuous enzyme, making the Yuh1 N88A and Yuh1m a better transamidase
compare to Yuh1 WT. This is not a unique phenomenon, as promiscuity has
reported to be a key factor in the evolution of new protein function. 24,25
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Figure 2-7: Michaelis-Menten kinetics measurement of Yuh1 variants.
Steady-state kinetics analysis of transamidation and hydrolysis for (A) Yuh1 WT,
(B) Yuh1 N88A and (C) Yuh1m in the presence of allylamine. Error bars
represent the standard error of two biological replicates.
Table 2-1: Michalis-Menten kinetics Parameters for hydrolysis and
transamidation with Yuh1 variants.
Hydrolysis

Transamidation

Km (µM)

kcat (s-1)

kcat/Km (M-1s-1)

Km (µM)

kcat (s-1)

kcat/Km (M-1s-1)

Yuh1
(no amine)
Yuh1

5±2

3.1±0.2

6±3 X 105

-

-

-

4±1

3.0±0.1

8±2 X 105

36±4

3.1±0.1

9±1 X 104

Yuh1 N88A

27±7

0.062±0.006

2.3±0.6 X 103

130±60

0.32±0.08

3±1 X 103

Yuh1m

17±4

0.092±0.006

5±1 X 103

51±11

0.34±0.02

6±2 X 103

Error represent the standard error of two biological replicates.

Autoubiquitination of Yuh1m
One of the properties of the ubiquitinating enzymes is that they are
capable of auto-ubiquitination.26 Here, having discovered a Yuh1 variant with
improved transamidation and impaired hydrolysis, we would like to investigate
whether Yuh1m is capable to self-ubiquitinate if its Lys is at close proximity. We
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decided to mimic the effect by introducing a lysine at the active site- crossover
loop which is at periphery of the Yuh1 active site. We chose Thr163, as the
crystal structure suggested that its side chain is pointing towards the catalytic
Cys, and is within 4 Å from the C terminus of ubiquitin (Figure 2-3).
We have generated the following Yuh1 variants: Yuh1 T163K and Yuh1m
T163K (herein referred as Yuh1qm) and reacted the Yuh1 variants with high
concentration of UbD77. SDS-PAGE analysis showed that only for Yuh1qm,
there are appearance of multiple protein bands at higher molecular weight. This
is accompanied with the decrease in the band representing Yuh1qm. The most
intense band (Band 1) has a molecular weight corresponding to Yuh1qm
modified with a single ubiquitin. While Band 2 has a higher molecular weight
compare to Band 1, its molecular weight is lower than a di-ubiquitinated Yuh1qm;
Band 3 with the highest molecular weight is consistent with a Yuh1qm decorated
with two ubiquitins (Figure 2-8A). We further validated these bands represent the
auto-ubiquitinated Yuh1qm through Western blot analysis (Figure 2-8B). On the
other hand, we observed no auto-ubiquitinating species for Yuh1 WT, Yuh1
T163K and Yuh1m. Next, we would like to investigate whether Yuh1qm can autoubiquitinate with pre-assembled ubiquitin chains. Here, we reacted Yuh1qm with
K48- and K63-linked ubiquitin dimers with UbD77 as the proximal ubiquitin. As
predicted, Yuh1qm rapidly auto-ubiquitinate with the ubiquitin dimers regardless
of the linkages (Figure 2-8C). Contrast with the previous auto-ubiquitination
assay with mono-ubiquitin, we only observed a single band corresponds to the
auto-ubiquitinating species, suggesting that Yuh1qm could not multi-ubiquitinate
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using ubiquitin chain as substrate. Here, we acknowledged that we could not
discriminate the fact that Yuh1qm could ubiquitinate another Yuh1qm, but the
inter-ubiquitination is a entropically unfavorable process. 27

Figure 2-8: Autoubiquitination of Yuh1 variants
SDS-PAGE analysis of auto-ubiquitination of Yuh1 variants (50µM) with UbD77
(200 µM) using (A) Coomassie blue and (B) Western blot with anti-Ub. The new
protein bands with higher molecular weight band represent auto-ubiquitinating
Yuh1qm. (C) SDS-PAGE analysis of auto-ubiquitination of Yuh1qm (5 µM) with
K48- and K63-linked ubiquitin dimers (20 µM).
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To identify the ubiquitination site, we performed tandem mass
spectrometry (MS/MS). As result indicated that Yuh1qm is capable of multimonoubiquitinated when UbD77 is the substrate, we decided to perform an in-gel
digestion on bands containing auto-ubiquitinating species with a combination of
trypsin and GluC (Figure 2-8A). We detected two peptides containing the diGlymodified (which is the signature of ubiquitination) Lys. They are peptides
containing the expected T163K and K66 which is located on a poorly resolved
region in the Yuh1 crystal and at the close proximity to the active site of Yuh1
(Figure 2-9A). While the MS/MS analysis for the purified di-ubiquitinated
Yuh1qm showed that K163 is the only Lys that is ubiquitinated (Figure 2-9B).

Figure 2-9: Tandem mass spectrometry analysis of auto-ubiquitinating
Yuh1qm
MS/MS spectrum showing peptides with ubiquitination site at (A) K66 and (B)
T163K of Yuh1qm.
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Our result has elucidated that Yuh1qm can auto-ubiquitinate site
specifically regardless of the ubiquitin topology. Hence, Yuh1qm has the potential
to be developed as the modular ubiquitin transamidase to generate ubiquitinprotein conjugate, that is the ubiquitin-yuh1 conjugate. However, a time course
assay using lower concentration of ubiquitin, which is 100 times lower compare
to the initial assay, revealed that hydrolysis of the auto-ubiquitinating Yuh1qm
occur with extended reaction times (Figure 2-10A and Figure B-1A). The yield
of the auto-ubiquitinating species is around 30% at the initial time point, and the
measured half-life is estimated to be 160 ± 60 s (Figure 2-10B). As a result,
large scale synthesis of ubiquitin-yuh1 conjugate with Yuh1qm remains
challenging.

Figure 2-10: Time course assay for auto-ubiquitinating Yuh1qm
(A) SDS-PAGE analysis of the auto-ubiquitinating Yuh1qm (1 µM) and UbD77 (2
µM) using SYPROTM Ruby. (B) Scatter plot of the auto-ubiquitinating species.
Hydrolysis data was fit to a single exponential decay. Error bars represent the
standard error of three biological replicates.
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Directed evolution of Yuh1qm
The poor stability of the auto-ubiquitinating Yuh1qm has precluded us
from applying Yuh1qm to synthesis ubiquitin-yuh1 conjugate in large scale. Here,
we decided to perform further engineering on Yuh1qm through yeast surface
display based directed evolution. An ideal Yuh1qm variant would have improved
auto-ubiquitination efficiency and further reduced intrinsic hydrolytic property.
First, we would like to investigate whether yeast surface display serves as
an ideal platform for our directed evolution strategy. In our strategy, we chose to
display Yuh1qm variants on the yeast surface through the well-established yeast
Aga1p-Aga2p display system, with the displayed Yuh1 variant flanking between a
HA and a c-Myc tag, which could be detected using anti-HA or anti-cMyc. 28,29,30
The Yuh1qm variants were then treated with biotinylated UbD77. We
hypothesized that the Yuh1qm variants with desired properties would have
higher biotin labeling on the cell surface and could be detected through
streptavidin. Under the circumstances where the fluorescent labeled antibodies
and streptavidin were used, the labeled yeast cell could be screened by
fluorescent-activated cell sorting (FACS) to identify and sort the most fluorescent
yeast cells (Figure 2-11A). To validate our strategy, we first transformed and
induced the yeast cells with yeast display vector containing either Yuh1 WT or
Yuh1qm. The cells were incubated with biotinylated UbD77 and and flow
cytometry analysis showed that only Yuh1qm is capable to label itself with
biotinylated ubiquitin (Figure 2-11B). Here, we would like to mention that labeling
at cMyc tag using antibody has negatively impacted the degree of auto-
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ubiquitination (aata not shown). Hence, although labeling at the C terminus cMyc
tag would ensure the identification of non-truncated Yuh1qm variants, we
decided to label the HA tag at the N terminus of Yuh1qm variants to estimate the
degree of Yuh1qm expression on the yeast surface.
We have generated a random mutagenized Yuh1qm library through errorprone PCR (epYuh1qm) with an estimated size of 10 7. Sanger sequencing of 10
clones showed that the library members contain 1-3 mutations per gene, with
mutated residues distributed evenly across Yuh1qm. We have performed five
rounds of screenings; in each screening, we were isolating the clones with both
high expression level of Yuh1 and high degree of ubiquitination. The sorted
clones were amplified and subjected for the subsequent rounds of sorting. In
addition, with each round we increased the stringency of the reaction conditions
by lowering the concentration of biotinylated UbD77 (Figure 2-11C). In addition,
the sorted yeast cells were incubated with biotinylated ubiquitin and the degree of
binding were investigated using flow cytometry. This was to ensure we did not
enrich for clones with higher binding affinities towards ubiquitin (data not shown).
At round 3, we started to observe the appearance of populations with
higher degree of ubiquitination. Sanger sequencing revealed that these clones
containing a consensus mutation at N164K. N164K is located at the active sitecrossover loop adjacent to the previously introduced T163K. Further sorting
showed the additional of two mutation hotspots; one at the periphery to the
catalytic Cys90 (Val86 and Leu139) and one is distant to both the active site and
the binding interaction surfaces with ubiquitin (Val52 and Ile202) (Figure 2-12).
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Figure 2-11: Directed evolution of Yuh1qm
(A) Scheme of yeast surface display for the directed evolution of Yuh1qm. The
displayed Yuh1 variants were detected with the labeling of the HA-tag fused to
the N terminus of Yuh1 with chicken anti-HA and Goat anti-chicken conjugated to
AlexaFluor® 647. The sorting of the library members was based on the degree of
ubiquitination on the Yuh1 which was immobilized on the yeast surface. The
ubiquitin was biotinylated and could be detected using streptavidin conjugated to
Alexa Fluor® 488. (B) Flow cytometry dot plot of yeast cells expressing Yuh1 WT
and Yuh1qm incubated with biotinylated UbD77. (C) FACS of the random
mutagenized epYuh1qm library. The frames and percentages designate the
fraction of yeast population isolated in each round of screening.
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Figure 2-12: Mutational hotspots
Crystal structure of Yuh1 (PDB ID: 1CMX) with mutational hotspots showing in
green (Left) and with the mutated residues highlighted (Right).
Based on the sequencing result, we further generated and expressed
these subsequent clones: Yuh1qm N164K (referred as Yuh1qm3.1), Yuh1qm3.1
V86F (Yuh1qm5.1), Yuh1qm3.1 V52L (Yuh1qm5.3) and Yuh1qm V52L/V86F
(Yuh1qm5.6). We investigated the auto-ubiquitination efficiency of these clones
through the aforementioned time course assay. Consistent with our screening
result, all the auto-ubiquitinating species for the engineered Yuh1qm variants are
significantly more robust compare to Yuh1qm (Figure 2-13A and Figure B-1).
Especially for Yuh1qm5.6, the yield for auto-ubiquitinating species approaching
90% at the initial time point (Figure 2-13B). Despite the improvement in the autoubiquitination efficiency, the engineered Yuh1 variants still experienced autohydrolysis. Nonetheless, the engineered Yuh1qm variants are more resistant to
hydrolysis which remove the ubiquitin modification from itself. Our result
indicated that the yield of auto-ubiquitinating species for Yuh1qm3.1, Yuh1qm5.1,
and Yuh1qm5.6 are around 30% even after 1 hr, while for the Yuh1qm, it could
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be barely detected (Figure 2-13A and Appendix Figure B-2). Fitting to single
exponential decay curves estimated the half-lives for auto-ubiquitinate
Yuh1qm5.1, Yuh1qm5.3, and Yuh1qm5.6 are 1400±100 s, 500±100 s and
800±100 s (Figure 2-13B). We could not fit the single exponential decay curve
for the auto-ubiquitinate Yuh1qm3.1.
The overwhelming enrichment of Yuh1qm variants containing the
consensus mutation at N164K leaded us to question the role of N164K in
stabilizing the auto-ubiquitinating species. Crystal structure of Yuh1 suggesting
that the carboxamide side chain of the Asn164 is pointing away from the catalytic
Cys90 (Figure 2-1A). We surmised that the N164K might be the preference
auto-ubiquitination site; upon ubiquitination, the C terminus of ubiquitin would
distance itself from the catalytic Cys90, hence reduce the degree of autohydrolysis. Indeed, a MS/MS analysis of purified auto-ubiquitinated Yuh1qm5.6
elucidated that N164K is the only ubiquitination site, supporting our supposition
(Figure 2-13C).
We further performed a Michaelis-Menten kinetics of Yuh1qm V52L/V86F
with UbD77 as substrate and allylamine as the nucleophile to investigate the
effect of replacing the Val residues with more hydrophobic and bulkier Leu or
Phe residues. The data analysis elucidated that while the steady-state kinetics
parameters for hydrolysis remain constant, for transamidadtion, the kcat reduced
by 45%, the Km decreased by 4-fold. Together, the catalytic efficiency for
transamidation improve close to 3 times compare to Yuh1m, and with a catalytic
efficiency transamidation to hydrolysis ratio at 3 (Figure 2-14 and Table 2-2).
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One of the possible reasons is that the higher degree of hydrophobicity at the
periphery of the active site enhances the interaction with the nucleophilic amine
at that region, thereby improves the transamidation efficiency. 31

Figure 2-13: Characterization of Yuh1qm variants.
(A) SDS-PAGE analysis of the auto-ubiquitinating Yuh1qm variants (1 µM) and
UbD77 (2 µM) using SYPROTM Ruby. (B) Scatter plot of the auto-ubiquitinating
species. Hydrolysis data was fit to a single exponential decay. Error bars
represent the standard error of three biological replicates. (C) MS/MS spectrum
showing peptides with ubiquitination site at N164K of Yuh1qm5.6.
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Figure 2-14: Michaelis-Menten
kinetics measurement of Yuh1m
V52L/V86F.
Steady-state kinetics analysis for
transamidation and hydrolysis in the
presence of allylamine. Error bars
represent the standard error of two
biological replicates.

Table 2-2: Michalis-Menten kinetics Parameters for hydrolysis and
transamidation with Yuh1m V52L/V86F.
Hydrolysis
Km

Transamidation
kcat/Km

Km

kcat (s-1)
(µM)

kcat/Km
kcat (s-1)

(x103 M-1s-1)

(µM)

5±1

12±3

(x103 M-1s-1)

Yuh1m
16±4

0.082±0.006

0.19±0.02

16±2

V52L/V86F
Error represent the standard error of two biological replicates.

Profiling DUBs activities using Ubiquitin-Yuh1 conjugates
We have shown the discovery of a Yuh1 variants, Yuh1qm5.6 that is
capable to auto-ubiquitinate with distinct pre-assembled ubiquitin chains site
specifically with high yield. Here, we generated ubiquitin-yuh1 conjugates with
different linkages as a model ubiquitin-protein conjugate substrate to study their
interactions with ubiquitin editors and readers. To ensure the ubiquitin-yuh1
conjugates do not auto-hydrolyze in the downstream biochemical assay, these
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ubiquitin-protein conjugates were treated with N-ethylmaleimide (NEM) to quench
the Yuh1qm5.6 after auto-ubiquitination.
Here, we investigated how the ubiquitin chain anchoring affects the
activities of deubiquitinases. As a proof of study, we synthesized free K48
ubiquitin dimers (Ub2) and K48 Ub2-Yuh1 conjugates, or known as the anchored
K48 Ub2. Both free and anchored K48 Ub2 were reacted with USP11, USP15 and
USP21.32,33,34 These deubiquitinases are members of the ubiquitin specific
protease (USP) family and are non-linkage specific. The chain cleavage activities
were determined through a gel-based assay. For anchored K48 Ub 2, Western
blotting with anti-His was performed to quantitate the disappearance of the K48
Ub2-His6-Yuh1qm5.6 and the appearance of mono-ubiquitin-His6-Yuh1qm5.6 and
His6-Yuh1qm5.6 simultaneously. For free K48 Ub2, SYPROTM Ruby stain was
performed to determine the disappearance of K48 Ub 2 and the appearance of
mono-ubiquitin. Our result elucidated that all USPs cleave the free and anchored
K48 Ub2 with similar efficiencies, although it was suggested that USP11 and
USP15 processed free K48 Ub2 at higher rate. Interestingly, all the USPs could
not remove the proximal ubiquitin from the Yuh1qm5.6 (Figure 2-15A and
Figure B-2). To ensure that NEM treatment did not interfere with the activities of
USP, we reacted the non-NEM treated anchored K48 Ub 2 with USP15. Our result
suggested that the rate of hydrolysis was approximately the same (Figure B-3A).
In addition, we also prepared free and anchored K63 Ub2 and performed
the same DUB assays. Our result was consistent to the data obtained using the
free and anchored K48 Ub2 (Figure 2-15B). These observations indicated that
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there is specificity towards the conjugated substrate, and implied that USP could
process the anchored ubiquitin chain from the distal end regardless of the
substrate.
Next, we profile the OTUB1 and OTUB2 activities with the free and
anchored Ub2. Both deubiquitinases belong to the ovarian tumor (OTU) families,
which are characterized by their linkage specific activities. OTUB1 specifically
processes K48-linked ubiquitin chain while OTUB2 selectively cleaves K48- and
K63-linked polyubiquitin.35,36,37 The activity of OTUB1 is reported to be enhanced
by the presence of E2 conjugating enzyme and an OTUB1-UBE2D2 fusion
protein was used in the DUB assay.38 As predicted, the free Ub2 were rapidly
processed by the OTU enzymes (Figure 2-16A and 16B). Surprisingly, the OTU
enzymes, even the improved OTUB1 variant could not hydrolyze the anchored
K48 Ub2 (Figure 2-16C). This was not due to the inhibition of Yuh1qm5.6, as the
free K48 Ub2 was hydrolyzed by the OTU enzymes in the presence of anchored
K48 Ub2 (Figure B-3B). On the other hand, OTUB2 is still capable to cleave the
anchored K63 Ub2 (Figure 2-16D).
Majority of the K48 linked Ub2 population adopt a ‘compact’ conformation;
this might lead to the difficulty of the OTU enzymes in accessing the anchored
ubiquitin subunits and hence, the lack of the ubiquitin chain cleavage activities.
Thus, we extended the chain length and the branching level of the anchored
polyubiquitin. We synthesized pre-assembled K48 Ub 3 and K6/K48 Ub3 and
transferred them onto Yuh1qm5.6 and profiled OTUB1 and OTUB2 activities
towards these anchored ubiquitin chain.39 Again, we observed no cleavage
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activity towards the anchored ubiquitin chain, but not the free counterpart (Figure
2-17A and 17B). Our data indicated that OTUB1 and OTUB2 activities are
influenced by the chain anchoring effect. Crystal structure of the OTUB1
conjugated to a ubiquitin aldehyde and UBE2D2~ubiquitin thioester intermediate
has been reported to mimic the interaction of OTUB1 with K48 Ub 2. A closer look
at the crystal structure suggested that substrate conjugated to K48-linked
ubiquitin chains might sterically hinder the OTUB1, thereby preventing the
anchored ubiquitin chain processing by OTUB1.40
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Figure 2-15: Profiling USP activities against free and anchored ubiquitin
dimers.
Cleavage of free and anchored (A) K48 Ub2 and (B) K63 Ub2 by USP11, USP15
and USP21. Error bars corresponded to standard error of three biological
replicates.
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Figure 2-16: Profiling OTU activities against free and anchored ubiquitin
dimers.
Cleavage of free (A) K48-linked and (B) K63-linked ubiquitin dimers and
anchored (C) K48-linked and (D) K63-linked ubiquitin dimers by OTUB1, OTUB1UBE2D2 (labeled as OTUB1*) and OTUD2.
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Figure 2-17: Profiling OTU activities against free and anchored ubiquitin
trimers.
Cleavage of free (A) K48-linked and (B) K6/48-linked ubiquitin trimers and
anchored (C) K48-linked and (D) K6/48-linked ubiquitin trimers by OTUB1,
OTUB1-UBE2D2 (labeled as OTUB1*) and OTUD2.

Discussion and Future Directions
In this study, we have reprogrammed a deubiquitinase, Yuh1 into a
ubiquitin transamidase which is capable to install defined ubiquitin chains on
itself site specifically. We would like to emphasize that the ubiquitinating
mechanism catalyzed by the Yuh1 is different to the conventional ATP
dependent enzymatic cascade, which require the generation of a high energy
ubiquitin~AMP, followed by transthioesterification between the catalytic Cys of
ubiquitinating enzymes before discharged onto the Lys of the substrate of
interest.41 For our engineered Yuh1, the activated ubiquitin species is resulted
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from the nucleophilic attack of ubiquitin with small adduct at the C terminal with a
highly reactive catalytic Cys. Hence, the application of reprogrammed Yuh1 in
preparing ubiquitin protein conjugate which bypassing the requirement of ATP
and ubiquitinating enzymes is conceptually new.
The catalytic efficiency of an enzymatic activity is determined by the
Michaelis-Menten constant, Km and the rate of catalytic turnover, kcat. For Yuh1
WT, the kcat of both hydrolysis and transamidation are similar, but the Km of
transamidation is an order of magnitude higher than hydrolysis. Hence, it is an
efficient hydrolase than a transamidase. A close inspection of the kinetic
parameters of our engineered Yuh1 mutant revealed that the kcat of both
hydrolysis and transamidation are heavily affected by the mutated residues.
Especially for hydrolysis, the kcat is two order of magnitude lower compare to the
Yuh1 WT. As a result, the catalytic efficiency of transamidation is higher than
hydrolysis and it manifests as a better transamidase, with the ratio of the catalytic
efficiency of transamidation to hydrolysis 28-folds higher than the Yuh1 WT.
Together, our engineering effort, which was a combination of targeted
mutagenesis, random mutagenesis and yeast surface display-based directed
evolution, has led to the emergence of a generalist with a catalytic promiscuity,
which could be a starting point for the evolution of improved new function. We
acknowledge that hydrolysis product is favored thermodynamically, and one of
the proposed strategies for future engineering effort is to further exclude water at
the catalytic cleft.
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Yuh1 does not display high specificity at P1’ site. In principle, it can accept
any nucleophilic amine for aminolysis. Here, we have shown that the improved
Yuh1 mutant can auto-ubiquitinate effectively at a Lys at the Asn164 position,
which is located at the periphery of the active site. This implies that if the Lys of a
substrate can be recruited to the proximity to the active site of Yuh1 for the
intermolecular ubiquitination to take place. 42 Hence, our Yuh1 mutant has the
potential to be developed as a modular ubiquitin transamidase. It will be
interesting to fuse a substrate binding module, for example, a nanobody which
recognizes our protein of interest, to the Yuh1 mutant and to investigate whether
it can be ubiquitinated by the Yuh1 mutant based on the induced proximity effect.
Our study also demonstrated that Yuh1 mutant is capable to autoubiquitinate with defined ubiquitin chain, regardless of the linkage and length with
similar efficiencies to generate anchored ubiquitin chains. We further established
that the utility of these anchored ubiquitin chains as the model substrates to
investigate their interactions with the ubiquitin interacting proteins, such as
deubiquitinases. We have discovered that the deubiquitinases which belong to
the non-linkage specific USP family, for example, USP11, USP15 and USP21
cleave the anchored ubiquitin chain from the distal end of the ubiquitin chains but
they could not remove the ubiquitin conjugated to Yuh1. Surprisingly, the linkage
specific OTU family, such as OTUB1 and OTUB2 are unable to process the
anchored K48 linked ubiquitin chains. This observation brings into the question
that the specificities of the OTU enzymes are not only solely determined by the
ubiquitin linkages. Our result also supports the study that elucidates the
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anchored K48 linked ubiquitin chains are resistant to the deubiquitinases
activities.43 Here, we highlighted that the nature of the ubiquitinated substrates
could play an important role in regulating the activities of these deubiquitinases.
Further characterization of the deubiquitinases should include the ubiquitinated
substrates to fully understand the biological relevance of the deubiquitinases.

Materials and Methods
Cell culture
Saccharomyces cerevisiae strain EBY100 (MATa AGA1::GAL1AGA1::URA3 ura352 trp1 leu2delta200 his3delta200 pep4::HIS3 prbd1.6R
can1 GAL) and yeast surface display vector, pCT used in yeast display were
kindly provided by Dr. Sarah Moore (Smith College).

Cloning
The Yuh1 cDNA (IDT technologies) was cloned into pET28b (Novagen) at NdeI
and XhoI (New England Biolabs) restriction site. The alanine mutants were
prepared through Phusion site directed mutagenesis (New England Biolabs). For
yeast display, the Yuh1 was PCR amplified (Lucigen) using pCT-yuh1_f(2) and
pCT-yuh1_r(2) (Appendix Table S2-1) and cloned into pCT vector at NheI and
BamHI (New England Biolabs) restriction site. All primers were purchased from
IDT DNA. All clonings were validated through Sanger sequencing.
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Protein expression and purification
Ubiquitin (Ub) was expressed in E. coli Rosetta (DE3) pLysS cells using 2xYT
media. To obtain 15N-labeled Ub, we supplemented M9 minimal media with

15N

ammonium chloride (Cambridge Isotope Laboratories). Labeled and unlabeled
Ub was purified as described previously.1 Briefly, cells were lysed in 50 mM Tris,
pH 7.4, 5 mM EDTA, 1 mM EGTA, 1 mM PMSF, 1 mM DTT, 0.02% (v/v) IGEPAL
and non-ubiquitin proteins were precipitated using 70% perchloric acid (1 ml for 6
L of cells). The clarified supernatant was dialyzed in 50 mM NH 4OAc, pH 4.4, 1
mM EDTA overnight before purifying through cation exchange chromatography
on an ÄKTA purifier (GE Healthcare). The equilibrate buffer was 50 mM NH 4OAc,
pH 4.4, 1 mM EDTA and the elute buffer was 50 mM NH 4OAc, pH 4.4, 1 mM
EDTA, 1 M NaCl. For

15N-labeled

Ub, MALDI-TOF analysis showed that the

percent of 15N incorporation was 95%.
To prepare Ub-allylamine, UbD77 (final concentration was 750 µM) was added to
a solution containing 50 mM HEPES pH 8, 1 mM EDTA, 100 mM allylamine
(Sigma-Aldrich), and 1 μM Yuh1m. The reaction took place at room temperature
for 100 min and was quenched by TFA. The reaction was buffer exchanged into
50 mM NH4OAc, 1 mM EDTA, pH 4.4 and purified through cation exchange
chromatography with the same buffer as mentioned above. Fractions containing
Ub-allylamine were identified by MALDI-TOF MS.
To prepare Ub-fluorescein- or biotinylated D77, Ub K63C D77 (final
concentration was 200 µM) was incubated at room temperature in a buffered
solution containing 50 mM HEPES pH 7.5, 5 mM MgCl2, 25 mM KCl, and 1 mM
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TCEP. To this mixture was added 1 mM 5-iodoacetamidofluorescein (SigmaAldrich) (or 1 mM EZ-linkTM iodoacetyl-PEG2-biotin (ThermoFisher Scientific)) in
10% DMSO and the resulting mixture was incubated at 37 oC overnight. The
reaction was monitored by MALDI-TOF MS and quenched with 10 mM DTT once
conversion was complete. The reaction was buffer exchanged into MilliQ water
before further purifying using a ZebraTM spin column, 7000 MW (Thermo
Scientific).
The 6xHis-tagged Yuh1 variants and OTUB1-UBE2D2, 6XHis MBP-tagged
USP11, USP15, OTUB1 and OTUB2, 6xHis SUMO-tagged USP21 were
expressed in E. coli BL21 (DE3) or Rosetta (DE3). The cells were lysed in 50 mM
sodium phosphate (or Tris), pH 8, 300 mM NaCl, 10 mM imidazole and the
proteins were purified using cobalt (Agarose Bead Technologies) or nickel
(Clontech) affinity chromatography. The equilibrate buffer was 50 mM sodium
phosphate (or Tris), pH 8, 300 mM NaCl, 10 mM imidazole and the elution buffer
was 50 mM sodium phosphate (or Tris), pH 8, 300 mM NaCl, 300 mM imidazole.
For 6xHis MBP-tagged protein, TEV cleavage reaction were performed to
generate tag-less protein; for 6xHis SUMO-tagged protein, ULP1 cleavage
reaction was performed. These proteins were further purified through anion
exchange chromatography (or size exclusion chromatography for USP21) on an
ÄKTA purifier (GE Healthcare). For the anionic exchange chromatography, the
equilibrate buffer is 50 mM Tris, pH 7.5, 1 mM DTT and the elution buffer is 50
mM Tris, pH 7.5, 1 mM DTT and 1 M NaCl. For the size exclusion
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chromatography, the running buffer is 50 mM Tris, pH 7.5, 300 mM NaCl and 1
mM DTT.

Transamidation activity assay
Transamidation reactions were carried out in a buffered solution containing 50
mM HEPES pH 8.0, 1 mM EDTA, 100 mM allylamine (Sigma Aldrich), 750 μM
Ub D77, and 1 μM enzyme. The reactions were quenched with a solution
containing 25 mM iodoacetamide (IAA) and 10% (v/v) acetic acid. Reactions
were monitored by MALDI-TOF MS as described below.

MALDI-TOF MS sample preparation and analysis
To 1 μl of quenched sample was added 1 μl of uniformly

15N-labeled

Ub D77 (5

μM). The resulting mixture was then added to 2 μl saturated sinapic acid in 40%
acetonitrile, 0.1% TFA. 2 μl of this mixture was then spotted on a 96-ground steel
MALDI target plate. MS spectra were acquired on a Bruker MALDI-TOF
microflex. For each spectrum, we collected a total of 1000 shots at 45% laser
power. Data processing was performed using FlexAnalysis software (Bruker).
Calibration curves were obtained for wild type Ub and Ub allylamine to quantify
the amount of hydrolysis and transamidation products.

Measuring kinetics of Yuh1 mutants using HPLC
Kinetic assays were carried out at room temperature in buffered solution
containing 50 mM HEPES pH 8.0, 1 mM EDTA, 100 mM allylamine, and either
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7.5 nM wild type Yuh1, or 500 nM of the Yuh1 N88A and Yuh1m variants. Initial
rates were measured by varying the concentration of fluorescein-labeled Ub D77.
Reactions were quenched at three different time points (0, 1, and 2 min). The
fluorescein-labeled components (Ub D77, wild type Ub, and Ub allylamine) were
then resolved by HPLC using a cationic exchange column (TOSOH Bioscience)
and a buffer containing 25 mM NH4OAc pH 4.4. A linear gradient of 0.15 – 0.35
M NaCl over 12 minutes was used to elute the Ub variants, which were detected
by absorbance at 494 nm. Quantification was based on a calibration curve of
fluorescein-labeled Ub D77. The kinetic data were analyzed using OriginPro and
fit to the Michaelis-Menten equation.

Ubiquitin chain synthesis
To prepare K48 Ub2 with UbD77 at the proximal site, 1 mM of UbD77 and 1 mM
Ub (or UbK6R/K48R for initial autoubiquitination assay with Yuh1qm) were
reacted with 0.2 µM E1 and 2 µM Cdc34 in a buffered solution containing 40 mM
Tris, 100 mM NaCl, 10 mM MgCl2, 10 mM ATP, and 0.2 mM DTT at pH 7.5. The
reaction was incubated at 37 oC overnight. For K63 Ub2, 0.75 mM of UbD77 and
0.75 mM of Ub (or UbK11R/K63R for initial autoubiquitination assay with
Yuh1qm) were reacted with 1 µM of E1, 8 µM of Ubc13-Mms2 in a buffered
solution containing 40 mM Tris, 10 mM MgCl2, 10 mM ATP, and 0.6 mM DTT at
pH 7.5. Again, the reaction was incubated at 37oC overnight.2 For K6/48 Ub3, 1
mM UbD77 and 2 mM UbK6R/K48R were reacted with 0.2 µM E1, 2 µM UbcH7,
0.45 µM NleL in a buffered solution containing 40 mM Tris, 10 mM MgCl2, 10 mM
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ATP, and 0.6 mM DTT at pH 7.5 for 37oC overnight. The reactions were
quenched using 10 mM DTT in 50 mM NH4OAc pH 4.4 solution for at least 30
min. Dimers were then purified using size exclusion chromatography using a
HiLoad Superdex 75 pg or cationic exchange chromatography on an ÄKTA
purifier. The running buffer for size exclusion chromatography was 50 mM Tris,
pH 7.5, 1 mM DTT, 300 mM NaCl. For cationic exchange chromatography, the
equilibrate buffer was 50 mM NH4OAc, 100 mM NaCl while the elution buffer was
50 mM NH4OAc and 1 M NaCl. To prepare K48 Ub3 with proximal UbD77, two
sequential Cdc34 reaction was performed. In the first reaction, 1 mM UbWT was
used to generate K48 ubiquitin chains; for the second reaction, 0.5 mM of K48
Ub2 purified from the previous reaction and 0.5 mM of UbD77 were used.

Autoubiquitination assay
Autoubiquitination reactions were performed at room temperature in a buffered
solution containing 50 mM HEPES pH 8.0 and 1 mM EDTA. For monoubiquitination reaction, 15 µM of the Yuh1 variant (wild type, T163K, Yuh1m, or
Yuh1qm) was used along with 200 µM of Ub D77; for di-ubiquitination reaction, 5
µM of Yuh1qm was reacted with 50 µM Ub chains with D77 at the proximal end.
Reactions were quenched by boiling in SDS-loading dye at different time points.
Western blot analysis was performed using the mouse anti-Ubiquitin (P4D1)
antibody (Enzo Life Sciences) at a 1:1000 dilution. We used the IRDye® 800CW
goat anti-mouse (LI-COR Biosciences) at a 1:15000 dilution as the secondary
antibody.
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Mass spectrometry analysis of autoubiquitination reactions
Autoubiquitination reactions were separated by SDS-PAGE using NuPAGE TM
12% Bis-Tris protein gels (ThermoFisher Scientific). The bands corresponding to
mono-ubiquitinated Yuh1qm were excised and prepared for in-gel digestion with
GluC at a 1:10 g/g ratio and trypsin at a 1:20 g/g ratio. K48 di-ubiquitinated
Yuh1qm and K63 tri-ubiquitinated Yuh1qm5.6 was purified by a size exclusion
chromatography (50 mM Tris, pH 7.5, 300 mM NaCl, 1 mM DTT) or anionic
exchange chromatography (50 mM Tris, pH 7.5, 1 mM DTT as equilibration
buffer and 50 mM Tris, pH 7.5, 500 mM NaCl, 1 mM DTT as elution buffer) and
lyophilized. The dry sample (0.35 µg/ul) was denatured for 1 h at room
temperature in a solution containing 25 mM ammonium bicarbonate and 8 M
urea. Digestion of di/tri-ubiquitinated Yuh1 variants were performed under the
same reaction conditions as described above.
Proteomic analysis was performed at the UMASS-Amherst Mass Spectrometry
Center. Briefly, nanoLC-MS/MS was conducted in an Orbitrap Fusion TM TribidTM
mass spectrometer (ThermoFisher Scientific). Digested peptides were separated
in a nanoLC column (Thermo Acclaim PepMap RSLC column, 75 µm X 15 cm)
with an Easy-nLC 1000 chromatography system (ThermoFisher Scientific) using
a linear gradient 0-50% buffer B (acetonitrile, 0.1% formic acid) over 50 min. The
eluted peptides were analyzed with resolution of 60000 and scan range of 3502000 m/z. Tandem mass spectrometry was performed using collision induced
dissociation (CID) with a 35% collision energy. The MS data were analyzed using
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Proteome DiscovererTM (ThermoFisher Scientific, Version 2.2) and SEQUEST HT
search engine.

Yeast growth and induction
Yeast were transformed using the Frozen EZ Yeast Transformation II kit (Zymo
Research) and plated on tryptophan-deficient dropout media (SDCAA plates; 20
g/L dextrose, 6.7 g/L yeast nitrogen base, 5 g/L casamino acids, 5.4 g/L
Na2HPO4, 8.56 g/L NaH2PO4.H2O, 15 g/L agar, 182 g/L sorbitol) for 2-4 days at
30 oC to identify successful transformants. Transformed EBY100 cells were
grown in 5 ml of SDCAA (20 g/L dextrose, 6.7 g/L yeast nitrogen base, 5 g/L
casamino acids, 5.4 g/L Na2HPO4, 8.56 g/L NaH2PO4.H2O) media overnight at 30
oC.

We then pelleted at least 5 X 10 7 cells and resuspended them in 5 ml of

tryptophan deficient dropout media containing galactose (SGCAA media; 20 g/L
galactose, 6.7 g/L yeast nitrogen base, 5 g/L casamino acids, 5.4 g/L Na 2HPO4,
8.56 g/L NaH2PO4.H2O) for induction to occur overnight at 20 oC.

Validation of the yeast display strategy
We harvested 5 X 106 cells and washed them with PBSF buffer (0.1% (v/v) BSA
in PBS buffer, pH 7.4). Cells were then labeled with chicken anti-HA (1:250
dilution in PBSF buffer) (Gallus Immunotech) for 30 min at room temperature.
Labeled cells were washed with PBSF buffer, aspirated, and incubated with 50
µM of biotinylated Ub D77 in 50 µl PBSF buffer for 10 min at room temperature.
Reactions were quenched with 5 µM of the pan-DUB inhibitor PR-619 (Selleck
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Chemicals). Since PR-619 is a reversible inhibitor, we also added it to the PBSF
wash buffer. Ubiquitinated cells were simultaneously labeled with a goat, antichicken antibody conjugated to Alexa 647 (1:100 dilution in PBSF buffer)
(InvitrogenTM) and streptavidin conjugated to Alexa 488 (1:100 dilution in PBSF
buffer) (InvitrogenTM) for 15 min on ice in a shielded box. Cells were washed one
last time with PBSF buffer and resuspended in the same buffer prior to
performing flow cytometry on a BD LSR Fortessa X20. We counted cells based
on both high expression levels of Yuh1 and high autoubiquitination efficiency.

Construction of the Yuh1qm library
The Yuh1qm gene was mutagenized using Mutazyme II, a commercially
available error prone polymerase (Agilent Technologies). The primers were the
same as those used to amplify the DNA library pool: pCT-yuh1_f2 and pCTyuh1_r2 (Appendix Table S2-1). To prepare electrocompetent yeast cells, a 25
ml culture of EBY100 cells were grown to OD 1.5 and treated with 25 mM DTT
for 15 min. Cells were then harvested, washed, and resuspended in 150 µl E
buffer (10 mM tris, pH 7.5, 270 mM sucrose, 2 mM MgCl2). Cells were
transformed with 1 µg of the NheI and BamHI digested plasmid and 4 µg of
amplified DNA library pool through electroporation. Transformed cells were serial
diluted and plated in -Trp dropout media for 2-4 days to estimate the size of the
library.
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Selection of Yuh1qm library displayed on the yeast surface
Five rounds of selection were carried out using fluorescent activated cell sorting
(FACS) on a BD FACS ARIA II with 488 nm (530/30 band pass collection filter)
and 640 nm (670/30 band pass filter) excitation lasers. For the first round of
selection, 2 X 108 cells displaying the Yuh1qm library were harvested and
washed with PBSF buffer. Aspirated cells were then incubated with biotinylated
Ub D77 using the procedure described above. In the second round, 50 µM of
biotinylated Ub D77 was incubated with 2 X 10 7 cells. In subsequent rounds, 5 X
106 cells were harvested and reacted with 5 µM, 0.5 µM, and 0.1 µM of
biotinylated Ub D77. The reaction time was 10 min for all selection rounds except
round 5, which was 5 min. At the end of rounds three and five, plasmids were
isolated from the enriched clones using a Zymoprep yeast plasmid miniprep kit
(Zymo Research) and electroporated into DH10β cells. Individual colonies were
grown, miniprepped and sequenced using pCT_yuh1_r2 to identify beneficial
mutations for autoubiquitination.

Validation of selected clones through autoubiquitination assays
Selected clones were amplified using the primers Yuh1_for_NdeI and
Yuh1_rev_Xhol, cloned into pET28b, expressed, and purified using the
procedure described above. For autoubiquitination, 1 µM of Yuh1qm variants
was incubated with 2 µM Ub D77 in 50 mM HEPES, pH 8.0, 1 mM EDTA.
Reaction progress was monitored by gel densitometry; gels were stained using

67

SYPROTM Ruby (InvitrogenTM) and scanned on a Typhoon FLA 9500 (GE
Healthcare). Data analysis was performed on Image Studio Lite (LI-COR
Biosciences). Data corresponding to the hydrolysis of the autoubiquitinated
species were fit to an exponential decay curve on OriginPro.

DUB assays with anchored and unanchored Ub chains
For maximum conversion of free ubiquitin chains into ubiquitinated Yuh1qm5.6, 5
µM of clone 5.6 was incubated with 2.5 µM ubiquitin chains (with Ub D77 as the
proximal unit) for 30 s. Reactions were quenched with 1 mM NEM and buffered
exchanged into MilliQ water. The resulting solutions were used directly in DUB
assays. For DUB assays, 0.5 µM of the USPs or 1 µM of OTUs were incubated
with the free and anchored ubiquitin chains. Reaction progress was monitored by
gel densitometry. For free ubiquitin chains, gels were stained with SYPRO TM
Ruby or transferred and blotted with the P4D1 anti-ubiquitin antibody (1:1000
dilution in 3% BSA, 0.1 % TWEEN; Enzo Life Sciences). For anchored ubiquitin
chains, gels were transferred and blotted with anti-6X His tag ® antibody (1:1000
dilutions in 3% BSA, 0.1% TWEEN; Abcam). All western blots were imaged on
Odyssey CLx imaging system (LI-COR biosciences). Data analysis was
performed on Image Studio Lite.
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CHAPTER 3
ENGINEER A NANOBODY SPECIFIC TOWARDS PROTEASOMEASSOCIATED UCH37
The work described in this Chapter is being prepared for manuscript submission.

Abstract
In eukaryotes cell, proteasome is the main protein degradation machinery
through ubiquitin proteasome system, and the proteasome-associated
deubiquitinases (DUBs) play an important role in regulating the activities of
proteasome by hydrolyzing the ubiquitin conjugated to the proteasome substrate.
Here, we report the engineering of nanobodies targeting UCH37, which is a
proteasome-associated deubiquitinase. Through a yeast display-based directed
evolution using ubiquitin conjugated UCH37 complex and nonpurified
proteasome associated UCH37 as antigen, we have discovered nanobodies with
sub-nanomolar affinities towards UCH37. These nanobodies also interact tightly
with recombinant UCH37 in complex with RPN13, which is a proteasome
associated subunit that recruits UCH37. We further demonstrated that one of our
engineered nanobody immunoprecipitates with the endogenous UCH37
containing proteasome in cellulo. We envision that these nanobodies could be
developed as intracellular tools to probe UCH37 spatially and temporally in a
cellular context.
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Introduction
In living system, the protein homeostasis is regulated through a delicate
balance between protein synthesis and protein degradation. For eukaryotes, the
ubiquitin-proteasome system (UPS) is the main protein degradation machinery,
which is responsible of 80% of the protein degradation. 1 26S Proteasome is a 2.6
MDa protein complexes, which can be categorized into 19S regulatory particle
(19S RP) and 20S core particle (20S CP). In the UPS, the proteasome substrate
is ubiquitinated through an ATP dependent enzymatic cascade, involving E1
activating enzymes, E2 conjugating enzymes, and E3 ligases. The proteasomal
ubiquitin receptors will recognize the ubiquitinated substrate, which lead to the
recruitment of proteasome to the substrate. The ubiquitin on the substrate will be
cleaved and removed by the proteasome-associated deubiquitinases (DUBs)
locating at the 19S RP, which are UCH37, USP14 and RPN11. The substrate will
then be unfolded by the ATPases, also situated at 19S RP. Next, the unfolded
substrate will be degraded by the proteolytic chamber in the 20S CP. 2,3,4,5
Every event in the ubiquitin proteasome system are regulated to ensure
the proper function of a proteasome. Here, we are interested in studying the role
of a proteasome associated deubiquitinase, UCH37. As suggested from its
name, UCH37 is a 37 kDa cysteine protease which belongs to the ubiquitin Cterminal hydrolase (UCH) family of deubiquitinases. Studies have elucidated that
UCH37 is recruited to proteasome through a 19S RP proteasome subunit,
RPN13, which association activates the activity of UCH37 (Figure 3-1A).6,7,8
Structural studies of UCH37 and UCH37 in complex with RPN13 have shown
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that UCH37 consists of a N terminal catalytic domain, which has a similar folding
motif with the other UCH members; and an extended ULD domain at the C
terminal (Figure 3-1B).9,10 Further studies has indicated that the ULD domain is
highly flexible, and is bound to the DEUBAD domain of RPN13. This interaction
changes the orientation of ULD domain relative to the catalytic domain of
UCH37, effectively “lock” the UCH37 in an active conformation. 11,12 Proteasomeassociated UCH37 has been suggested to be an anticancer drug target and the
understanding of the regulation on UCH37 is crucial in the therapeutic
development.13,14

Figure 3-1: Proteasome-associated UCH37
(A) 3D reconstruction of yeast 26S proteasome-Ubp6 (homologous to human
USP14) complex (PDB ID: 5A5B).15 Cryo-EM structure is used as a
representative scheme to depict the orientations of USP14 and UCH37 on
proteasome. (B) UCH37 interacts with RPN13 at the C terminal ULD domain of
UCH37 and the C terminal DEUBAD domain of RPN13.

The paradigm of study the function of a protein is through genetic
experiment, which result in irreversible modification of the target protein. On
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other hand, intrabodies or intracellular antibodies have emerged as an alternative
for probing the biological functions of protein in cellulo and in vivo.16,17 Here, we
proposed to utilize nanobody as the next generation tool to investigate the
proteasome associated UCH37 in a cellular context. Nanobody, or V HH antibody,
is the single monomeric variable antibody domain of the heavy chain only
antibody, which is found in the Camelidae family (Figure 3-2A). Nanobody has
high stability, and it recognizes its epitopes using its three complementary
determining regions (CDRs), which is similar to the antigen-interacting surface of
an antibody (Figure 3-2B). In contrast to the conventional antibody, which is
composed of two heavy and light chains linked by disulfide bond with size
approximate to 150 kDa, nanobody is monomeric, with molecular weight around
15 kDa. Hence, it could be genetically expressed and folded properly inside living
cells. Together, using nanobody as an intrabody would enable us to probe the
protein of interest in real time without genetic manipulation on the endogenous
protein.18,19

Figure 3-2: Nanobody
(A) Comparison of conventional antibody, heavy chain only antibody and
nanobody. The variable domain of the heavy chain (gray) and light chain (green).
(B) Crystal structure of a nanobody (PDB ID: 5VNV) with its complementary
determining regions (CDRs) highlighted.
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Nanobodies are generally produced through the immunization of Ilamas
(or camel) using the antigen protein. The immunized library is then displayed on
the phage surface followed by biopanning to isolate the potential nanobody
binders.19 Meanwhile, studies have shown that synthetic nanobody library display
on the yeast surface has been successfully used to identify nanobody binders
towards a variety of proteins. The in vitro screening conditions offer by synthetic
nanobody libraries have enabled the discovery of conformational selective
nanobodies and nanobodies targeting challenging proteins, such as membrane
proteins.20,21
Here, we decided to engineer a nanobody specific towards proteasomeassociated UCH37. By using a synthetic nanobody library displayed on yeast
surface and ubiquitin conjugated UCH37∙RPN13 DEU at its catalytic Cys as
antigen, we have isolated several nanobody binders, probably targeting the
exosite of UCH37. We further performed affinity maturation using random
mutagenesis and nonpurified proteasome associated UCH37 as antigen and
have identified nanobodies with sub-nanomolar affinities towards free UCH37
and interact tightly with UCH37∙RPN13. We also demonstrated that one of the
isolated nanobody immunoprecipitates with endogenous UCH37 containing
proteasome in cellulo. Our result suggested that these nanobodies could be
developed as the UCH37 intrabodies to probe proteasome-associated UCH37 in
a cellular context.
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Result
Generation of the UCH37 nanobodies
Using a synthetic nanobody library (Appendix A), we designed a
screening strategy to isolate the nanobodies binders for UCH37. The
straightforward approach is to use purified UCH37 protein as the antigen and to
select for the clones which bind to the exposed surfaces of UCH37. Nonetheless,
manipulation of the full length UCH37 protein has been problematic; free UCH37
is prone to dimerize and further oligomerize in micromolar range in vitro.22
Furthermore, these UCH37 oligomers adopt an auto-inhibition conformation, with
one of the helixes of a subunit blocks the ubiquitin binding site of the other
subunit.10 As mentioned in the introduction section, UCH37 interacts with the
DEUBAD domain of RPN13 (RPN13DEU), which will disrupt the dimerization of
UCH37, leading to the formation of UCH37∙RPN13 DEU heterodimer which
activates the catalytic activities of UCH37 towards ubiquitin-7-amido-4methylcoumarin (UbAMC).8,11,12 Our group further showed the UCH37∙RPN13 DEU
is more reactive in hydrolyzing Lys48 linked branched ubiquitin chains. As our
goal is to identify nanobodies targeting proteasome bound UCH37, purified
UCH37∙RPN13DEU is the biological relevant protein to be used as the antigen for
our directed evolution scheme.
Another consideration is that most deubiquitinases shared a similar and
conserved S1 site to recognize ubiquitin; these enzymes interacts extensively
with the C terminus of ubiquitin at the S1 binding site. 23,24 It is a well-known
observation that directed evolution has the tendency to isolate binders targeting
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the substrate binding site which has a well-evolved binding cleft. Hence, one of
the concerns of our screening strategies is the generation of low specificity
nanobodies targeting the conserved S1 ubiquitin binding site. This motivated us
to prepare a UCH37∙RPN13DEU conjugated to the inhibitor ubiquitin
propargylamine (Ub-PA) at its catalytic Cys88 as the antigen for our screening
(Figure 3-3A). We hypothesized that using the UCH37∙RPN13 DEU with the
blocked S1 site will enhance our chance of identifying exosite binders with
improved specificity. We recognized that the caveat of utilizing protein complex
as antigen is that we might selecting for nanobodies targeting the non-desirable
epitope, which are RPN13DEU and ubiquitin; negative selection could be
performed to circumvent this issue and careful characterization need to be
conducted to ensure the binding properties of the selected nanobodies.
Our initial yeast display selection scheme included two rounds of magnetic
activated cell sorting (MACS) followed by two rounds of fluorescent activated cell
sorting (FACS) using the biotinylated ubiquitin conjugated UCH37∙RPN13 DEU.
The biotin was introduced as a mean to detect our antigen in the sorting. Here,
we adopted the established AviTag technology to biotinylate site specifically at
the N terminus of ubiquitin.25 In each round, a minimum of 10X of oversampling
of the library size was used to avoid the loss of the unique clones. Due to its high
screening capacity, which is close to 1010 of cells and its ability to bind to even
the weak binders in micromolar range, MACS was performed at first to reduce
the size of our initial library, allowing subsequent rounds to be carried out using
FACS.26 For FACS, we increased the screening stringency by lowering the
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concentration of the antigen with each successive rounds. We observed the
emergence of a tight binding populations at the end of FACS (Figure 3-3B).
Sanger sequencing revealed that there was an overwhelming enrichment of a
single clone, we named it as NbAI.1.
To identify additional nanobodies targeting other interaction surfaces of
UCH37, we screened the sorting library against UCH37∙RPN13 DEU in complex
with NbAI.1. By blocking the epitope of UCH37 recognized by NbAI.1, we
reasoned this strategy will bias our screening result in isolating nanobodies either
bind outside the S1 ubiquitin and NbAI.1 binding site or with improved binding
kinetics that could compete of NbAI.1 (Figure 3-3C). Similarly, we prepared our
biotinylated antigen by fusing the AviTag at the N terminus of UCH37. The
screening led to the discovery of two different nanobodies, herein referred as
NbAII.1 and NbAII.2 (Figure 3-3D). Based on phylogenetic analysis, the
identified NbAI.1, NbAII.1 and NbAIII.1 are distinct (Figure 3-4). Interestingly, the
CDR2 of NbAII.1 has one additional amino acid, which could be a result of
serendipity or synthesis error during preparation of the synthetic library. We
further interrogated the binding of the identified nanobodies towards
UCH37∙RPN13DEU based on the titration of nanobodies immobilized on yeast
surface (Figure B-4); NbAII.2 was not further studied due to its unsatisfactory
binding profile.27,28
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Figure 3-3: Initial screening strategy for the isolation of UCH37 nanobodies
(A) Scheme showing the antigen design and (B) FACS result in the screening against
ubiquitin conjugated UCH37∙RPN13DEU. (C) Scheme showing the antigen design and (D)
FACS result in the screening against UCH37∙RPN13DEU in complex with NbAI.1. The
frames and the percentages designate the fraction of yeast population isolated in each
round of sorting.

Figure 3-4: Amino acid sequences of the enriched clones
The diversified residues in the CDRs are highlighted in colored box.
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Affinity maturation of the proteasome-associated UCH37 specific Nbs
As our goal is to utilize the nanobody as an intracellular probe towards
proteasome associated UCH37, our ideal nanobody should recognize the
proteasomal UCH37 in a cellular context. Here, we performed affinity maturation
to improve the binding affinities of our identified nanobodies. As mentioned,
proteasome is a multi-protein complexes consist of around 30 subunits. Studies
have shown that the constitutive proteasome subunits could be fused to affinity
tag to facilitate the purification of proteasome from the mammalian cell. 29,30
Especially affinity tagged RPN11 has been extensively used to purified the
UCH37 containing proteasome. Meanwhile, study has shown that yeast surface
Aga1p-Aga2p display platform is compatible for cell lysate-based antigen. 31
Hence, we have devised a new yeast display scheme using the cell lysate of a
stable HEK293 cell line expressing RPN11-His6-TEV-Biotin-His6 (HEK293RPN11HTBH)

as our antigen in the positive screening step. To prevent the enrichment of

nanobodies that interact with the random cellular proteins or other proteasomal
subunits in the cell lysate, our selection scheme also incorporated a negative
selection scheme using the cell lysate of a CRISPR/Cas9 mediated UCH37
knockout HEK293RPN11-HTBH (ΔUCH37 HEK293RPN11-HTBH) as the antigen (Figure
3-5A). By alternating between the positive screening and negative selection, we
hypothesized this will ensure the isolation of nanobodies binding specifically to
proteasome-bound UCH37 in a native environment.
In our initial screening, NbAI.1 showed the highest binding affinity in the
titration experiments. Therefore, we generated a random mutagenized NbAI.1

81

library through error prone PCR. Upon transformation, we obtained around 2x10 7
clones. Further inspection of our random mutagenized library through next
generation sequencing yield 338904 raw reads, with 91% of the ensembles are
in frame. Among the library members, 31% are unique with 17% represent the
original NbAI.1 (Table 3-1). As a result, the effective size of our random
mutagenized NbAI.1 library is estimated to be around 6x10 6 variants. A random
sampling of 500 clones suggested that there are 1-7 mutations in the NbAI.1
variants. We further validated the feasibility of our screening strategies by
incubating the induced library with the WT and UCH37 KO HEK293 RPN11-HTBH cell
lysate and detected a visible difference in the degree of antigen binding (Figure
B-5).

Table 3-1: Overview of sequencing data of random mutagenized NbAI.1
library
DESCRIPTION NO. OF READS PERCENTAGE (%)
RAW
338904
100.0
IN FRAME
307933
90.9
UNIQUE
105222
31.0
NBAI.1
58406
17.2
Raw data represents the total number of merged reads with low quality data
removed; in frame is the number of reads containing in frame nanobody
framework; unique read is the number of nanobody with unique sequence; and
NbAI.1 is the number of reads with no mutation.
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Figure 3-5: Affinity maturation of the proteasome-associated UCH37
nanobodies
(A) Positive screening and negative selection scheme and (B) FACS result using
HEK293RPN11-HTBH cell lysate. The frames and the percentages designate the
fraction of yeast population isolated in each round of sorting.
Next, we performed our enrichment strategy through FACS; we started by
one round of positive screening, followed by one round of negative selection and
two rounds of subsequent positive screenings with diluted cell lysate (Figure 35B). Upon sorting, the size of the isolated clones is reduced to be 10 4 clones.
The gene of the pre- (the random mutagenized NbAI.1 library) and postselection clones were pooled together and subjected to multiplex next generation
sequencing to identify the enriched variants. The number of reads assigned for
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the post- selection clones were in the order of 10 5 to ensure the all the isolated
nanobodies were sequenced. Not surprisingly, with close to 20% of NbAI.1
presence in the random mutagenized library, the clones with the highest
frequencies of the post-selection clones are NbAI.1 (Table 3-2). This explained
why we did not discover any clones with mutations was being enriched in our
screening through sanger sequencing. To identify the beneficial mutations, we
calculated the enrichment ratio of the clones based on the following equation: 32
𝐸𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 𝑟𝑎𝑡𝑖𝑜 =

𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑜𝑓 𝑐𝑙𝑜𝑛𝑒
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑜𝑓 𝑐𝑙𝑜𝑛𝑒

,

The frequency of pre-selection clone was set at minimum to one.
It is crucial to note that only around 4x10 5 reads was assigned to the preselection nanobodies, which was far less than the size of the transformed library
(only 2%) and that a great portion of nanobodies were not sequenced. Hence, for
calculation purpose, the frequency of the pre-selection clones was set to one at
minimum.

Table 3-2: Overview of the sequencing data of the post selection clones
DESCRIPTION

NO. OF
PERCENTAGE (%)
READS
Raw
124883
100.0
NbAI.1
23800
19.1
Raw data represents the total number of merged reads with low quality data
removed and NbAI.1 is the number of reads with no mutation.

Our result indicated that the top 20 enriched clones showed the
enrichment ratio in the range of 100~400 (Figure 3-6A). Especially the top three
clones have consensus mutations at three positions, they are Q1R (or K), H99Y
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and A109P (Figure 3-6B). Moving down the list revealed another enriched
mutation at R33P. Not surprisingly, most of the consensus mutations, R33P,
H99Y and A109P are located at the CDRs, which are the regions responsible for
antigen recognition. We further mapped those mutated residues on a solved
crystal structure of nanobody with 85% of sequence identity (PDB ID: 6O3C); it
was suggested that these residues are clustered (Figure 3-6C).33
We further displayed these enriched NbAI.1 variants on the yeast surface
and interrogated their binding towards the cell lysate generated from
HEK293RPN11-HTBH. Compare to NbAI.1 and NbAI.1 variant without the enriched
mutations, variants containing single mutation at Q1K, R33P, H99Y and A109P
showed higher degree of binding, supporting our NGS data that these mutations
are beneficial (Figure 3-7). We did not observe improved binding with the
incubation with the UCH37 KO HEK293 RPN11-HTBH, suggesting that these
nanobodies are specific towards proteasome-associated UCH37 (Figure B-6).
Here, NbAIII.15 (Q1R/L80Q/H99Y/A109P) and NbAIII.16 (Q1R/H99Y) which
combine the beneficial mutations were chosen for further studies. We would like
to emphasize that L80Q was a random mutation that was originated from the
cloning using the plasmid extracted from a sorted clone and was not a mutation
identified in our NGS data. In addition, we observed that the recombinantly
expressed nanobody containing R33P consistently precipitated during protein
purification and was not further studied.
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Figure 3-6: Enriched NbAI.1 variants
(A) Enrichment ratio and (B) the sequence alignment of the top 20 enriched
clones. The CDRs are featured in the colored box. The mutations are printed in
red and the consensus mutations are highlighted by asterisk (*). (C) Crystal
structure of nanobody (PDB ID: 6O3C) with enriched mutations colored in red.
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Figure 3-7: Investigation of the enriched mutations
Flow cytometry plots showing the binding of the yeast surface displayednanobodies containing the enriched mutations towards the cell lysate generated
from the HEK293RPN11-HTBH. The enriched mutations are highlighted in bold. The
frames designate the percentages fraction of yeast population with improved
degree of binding.

Characterization of Nanobodies
For the characterization of the protein-protein interactions (PPIs) of our
identified nanobodies with proteasomal UCH37, we performed the biophysical
characterization of these nanobodies in different stages. We started by accessing
the binding of the nanobodies with UCH37 qualitatively through a pull-down
assay. Here, we expressed the nanobodies as a HaloTag fusion construct and
incubated these nanobodies with the recombinantly expressed UCH37 and
UCH37∙RPN13. Our result elucidated that all nanobodies can capture the purified
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UCH37 and UCH37∙RPN13, although the SDS-PAGE analysis suggested that
the interaction between NbAII.1 with UCH37∙RPN13 was apparently weaker
(Figure 3-8A and B). We recognized that the concentration of the full length
UCH37 used in this in vitro pull-down assay was at the micromolar range, when
the UCH37 exists in the dimeric or oligomeric status; the result did not provide
insight in how the UCH37 polymers interacts with the nanobodies.

Figure 3-8: Pull-down assay with recombinant UCH37
In vitro pull-down assay of HaloTag nanobodies with recombinantly expressed
(A) full length UCH37 and (B) UCH37∙RPN13. Ctrl is a random nanobody which
does not interact with UCH37 and its binding partner.

Next, we characterized the bindings of the nanobodies with free UCH37
quantitatively through surface plasmon resonance (SPR). Here, to ensure the
binding measurement was between the nanobodies and free UCH37, UCH37 in
nanomolar range was flowed over the immobilized nanobodies. Our result shown
that these nanobodies are tight binders to UCH37, with KD ranges from low to
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sub-nanomolar affinities (Figure 3-9). NbAI.1 and its derivatives, NbAIII.15 and
NbAIII.16 bind to UCH37 at 0.3±0.1 nM, 0.13±0.02 nM and 0.21±0.05 nM
respectively, while the KD of NbAII.1 is 5.6±0.8 nM (Table 3-3). Our result also
indicated that for NbAIII.15 and NbAIII.16, the improvements in the binding are
mainly derived from the slower dissociation rate.

Figure 3-9: Kinetic analysis of the binding of nanobodies with free UCH37
Representative double referenced sensorgrams (red) of full length UCH37
binding to immobilized NbAI.1 (Top left), NbAII.1 (Top right), NbAIII.15 (Bottom
left) and NbAIII.16 (Bottom right). Binding experiments were performed in singlecycle kinetic format at 25oC.34 Black line represents the fitted sensorgrams.
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Table 3-3: Binding parameters of the UCH37 nanobodies
Variants

kon (x105 M-1s-1)

koff (x10-4 s-1)

KD (nM)

NbAI.1

3.9±0.6

1.3±0.4

0.3±0.1

NbAII.1

0.77±0.2

4.3±0.6

5.6±0.8

NbAIII.15

3.08±0.02

0.39±0.01

0.13±0.04

NbAIII.16

3.7±0.3

0.7±0.2

0.21±0.05

Error represent the standard error of two biological replicates.

Studies have shown that UCH37 changes its conformation, mainly at the
C terminal ULD domain and the crossover loop upon binding with RPN13. We
would like to validate the interactions between the nanobodies with the
UCH37·RPN13DEU in addition to our earlier qualitative pull-down assay. Here,
these nanobodies were incubated with UCH37∙RPN13 DEU at 1:1 ratio and were
analyzed using size exclusion chromatography coupled with multi angle light
scattering (SEC-MALS). SEC-MALS result indicated that NbAI.1 and its
derivatives, NbAIII.15 and NbAIII.16 co-eluted with UCH37∙RPN13 DEU in a
homogenous peak, with a measured mass at 53 ± 3 kDa, 59 ± 2 kDa, and 59.2 ±
0.5 kDa (increase from 45 ± 3 kDa for UCH37∙RPN13 DEU). We did not observe
co-eluted peak in the NbAII.1 and UCH37∙RPN13 DEU mixture (Figure 3-10). This
supported our findings in the in vitro pull-down assay, suggesting that the binding
interaction of NbAII.1 with UCH37 might be sensitive to the change of
conformation in the UCH37∙RPN13DEU.
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Figure 3-10: SEC-MALS analysis of nanobodies incubated with
UCH37∙RPN13DEU.
Representative elution profiles of NbAI.1 (Top left), NbAII.1 (Top right), NbAIII.15
(Bottom left) and NbAIII.16(Bottom right) incubated with UCH37∙RPN13 DEU at 1:1
ratio (Blue). The black and red plots represent the elution profile of just nanobody
and just UCH37∙RPN13DEU.

Together, our biophysical characterization suggested that NbAIII.15 could
be the most promising nanobody to be developed as an intrabody for
proteasome-associated UCH37 due to its high affinity towards full length UCH37
and its interaction with UCH37∙RPN13. We are interested in examining the
possible epitopes recognized by NbAIII.15. Limited proteolysis has been applied
to probe the interacting sites of protein complexes. These binding surfaces would
be occluded from the protease while the exposed area would be readily cleaved.
These proteolytic fragments could be detected through mass spectrometry, such
as matrix-assisted laser desorption/ionization- time of flight mass spectrometry
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(MALDI-TOF MS) and be identified based on the specificity of protease. This
would define the location of proteolysis and give insight into the binding
interactions.35 Here, we performed limited proteolysis on the native
UCH37∙RPN13DEU and UCH37∙RPN13DEU in the presence of excess NbAIII.15 (in
1:2 ratio) using LysC. Our MALDI-TOF MS result elucidated that while the
nanobody and RPN13DEU were mostly resistant to proteolysis, UCH37 was not;
the MS spectrum also revealed that the apo UCH37∙RPN13 DEU has different
cleavage pattern compare to NbAIII.15∙UCH37∙RPN13 DEU complex (Figure 311A). The identification of these proteolytic fragments indicated that the catalytic
domain of the UCH37 in the ternary complex remained mostly intact, in contrast
to the apo UCH37∙RPN13DEU. In addition, certain regions on the UCH37 of the
ternary complex were resistant towards proteolysis compare to the
UCH37∙RPN13DEU. These regions, one is the solvent exposed surface delineated
by K57 at β2, K206 and K210 at H7, the other located at the opposite end and
included the K23 at H1, K228 at H8, and K281 at H9, where both H8 and H9
belongs to the ULD domain (Figure 3-11B and Table 3-4). These surfaces could
serve as the possible binding site for NbAIII.15. Not surprisingly, both sites did
not include the reported primary ubiquitin binding site, further verifying that
NbAIII.15 is an exosite binder for UCH37∙RPN13 DEU. While for NbAIII.15, we
observed peptide fragments originated from the LysC proteolysis at sites away
from the CDRs (Table B-2). Further characterization using X-ray crystallography
and hydrogen deuterium exchange mass spectrometry are now being conducted
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to obtain high resolution structure of the NbAIII.15∙UCH37∙RPN13 DEU complex to
give detailed structural information at atomic level.

Figure 3-11: Limited proteolysis of UCH37∙RPN13 DEU and NbAIII.15 with
UCH37∙RPN13DEU
(A) Representative MALDI-TOF MS spectrum for the limited proteolysis of
UCH37∙RPN13DEU (Left) and NbAIII.15 with UCH37∙RPN13DEU (Right) by LysC.
Red star indicated the proteolytic fragments only observed in UCH37∙RPN13 DEU;
black star showed the full length nanobody and proteolytic fragments originated
from NbAIII.15. (B) Crystal structure of UCH37∙RPN13DEU (PDB ID: 4UEL) with
the cleavage sites observed only in UCH37·RPN13 DEU highlighted. Cleavage
sites which are unique to UCH37∙RPN13DEU could potentially be the epitopes
recognized by NbAIII.15.
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Table 3-4: MALDI-TOF MS analysis of the limited proteolysis of
UCH37∙RPN13DEU and NbAIII.15 with UCH37∙RPN13DEU
UCH37∙RPN13DEU

NbAIII.15∙
UCH37∙RPN13DEU

Measured Mass
[M+H]+

Measured Mass
[M+H]+

Calculated
Mass [M+H]+

Observed amino
acid residues

1516
1516
1519
289-300
2129
2130
211-228
2527
2527
24-45
2679
2679
58-81
3242
3241
127-154
3406
3405
3405
235-265
3699
3698
82-115
4074
4073
46-81
5436
5436
235-281
5823
5823
155-206
8864
8862
8864
159-234
9251
9250
9252
155-234
Only proteolysis fragments generated from UCH37 were listed here. These
fragments were detected in two biological replicates. The identities of the
proteolysis fragments were determined using ProteinProspector. 36

Nanobodies as intrabodies for proteasome-associated UCH37
The nanobody that is suitable for live cell application should interact
specifically with proteasomal UCH37 in cellulo. Here, we performed transient
transfection of HEK293FT cells with HA-FLAG-HaloTag nanobodies. 37
Immunoprecipitation with HaloLinkTM resin followed by immunoblotting analysis
showed that NbAI.1, NbAIII.15 and NbAIII.16 captured the endogenous UCH37.
In addition, NbAIII.15 also immunoprecipitated with RPN13, other constitutive
19S RP subunits such as RPN11 and RPT2, and 20βs, which is a 20S CP
subunit. While the negative control Nb, NbCtrl and NbAII.1 did not
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immunoprecipitate with UCH37 (Figure 3-12). Finally, we performed
immunoprecipitation followed by mass spectrometry (IP-MS) to investigate the
specificity of NbAIII.15 in the context of cellular proteome and to identify de novo
PPIs. Immunoprecipitated proteins were eluted using urea following by trypsin
digestion and the resulting peptides were subjected to nanoLC-MS/MS. Our data
showed that NbAIII.15 specifically captured UCH37 and the proteasome subunits
compare to NbCtrl, further supporting our immunoblotting result (Table 3-5 and
Figure B-7). In addition, it was suggested that NbAIII.15 interacts with INO80E,
which is a subunit of INO80 complex. It has been reported that UCH37 could be
recruited to INO80 complex to regulate the DNA transcription and DNA repair of
the INO80 chromatin-remodeling complex through INO80G. 38 Structural studies
revealed that UCH37 binds to INO80G at its DEUBAD domain, adopting an
inhibitory conformation.11,12 Nonetheless, the absence of other INO80 subunits
may suggest that NbAIII.15 preferentially interacts with proteasome associated
UCH37, which might be due to the unfavorable interactions with the UCH37 in a
different conformation. In addition, INO80 complex exists in nucleus exclusively,
and there is a possibility that the NbAIII.15 shows predominant cytoplasmic
location, which lead to the lack of interaction with the INO80 complex associated
UCH37. Further experiments need to be conducted to elucidate the interactions
between the UCH37 in distinct conformations. Together, we have demonstrated
that the isolated nanobodies, particularly NbAIII.15 could be developed as
intrabody for proteasome-associated UCH37.
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Figure 3-12: Immunoprecipitation of endogenous UCH37 by intracellularly
expressed nanobodies
Representative Western blots showing the transient expression of nanobodies
and the immunoprecipitation of UCH37, RPN13, RPN11, and RPT2, which are
the 19S RP subunits and 20βs, which is the 20S CP subunits by intracellularly
expressed NbAIII.15 (Left). A Cryo-EM structure of yeast proteasome (PDB ID:
6J2X) is shown as a representative scheme to depict the immunoprecipitated
proteasomal subunits (Right). Immunoprecipitations were performed in two
biological replicates.
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Table 3-5: Complete list of NbAIII.15 interacting proteins
Accession

Gene
Symbol

Description

# Unique
peptides
Rep 1 Rep 2

Ubiquitin carboxyl-terminal
UCHL5
11
16
hydrolase isozyme L5
Proteasomal ubiquitin receptor
Q16186
ADRM1
11
7
ADRM1
26S proteasome non-ATPase
Q15008
PSMD6
30
17
regulatory subunit 6
26S proteasome non-ATPase
P51665
PSMD7
16
11
regulatory subunit 7
26S proteasome non-ATPase
O00231
PSMD11
30
17
regulatory subunit 11
26S proteasome non-ATPase
Q9UNM6
PSMD13
26
15
regulatory subunit 13
26S proteasome non-ATPase
O00487
PSMD14
15
10
regulatory subunit 14
26S proteasome regulatory
P35998
PSMC2
33
24
subunit 7
26S proteasome non-ATPase
O43242
PSMD3
35
26
regulatory subunit 3
P17066
Heat shock 70 kDa protein 6
HSPA6
8
3
DnaJ homolog subfamily B
P25685
DNAJB1
5
4
member 1
Q8NBZ0
INO80 complex subunit E
INO80E
5
4
ZW10 interactor
O95229
ZWINT
3
6
RING finger and CHY zinc finger
Q96PM5
RCHY1
6
3
domain-containing protein 1
Proteins which were identified in both biological replicates with p<0.05 are
shown. Rows shaded in blue represent known proteasome subunits. Row
shaded in beige shows a component of INO80 complex. UCH37 is reported to
interact with INO80 complex through interaction with INO80G. MS data
acquisition and analysis were performed by Yanfeng Li.
Q9Y5K5

Discussion and Future directions
In this chapter, we have identified nanobodies specific towards
proteasome associated UCH37 using a yeast surface display based synthetic
nanobody library with an effective size of 2 x 10 7. The in vitro yeast display
platform has allowed us to have a greater control on the antigen presented in our
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screening strategy. In our effort to identify UCH37 binders, we chose ubiquitin
conjugated UCH37∙RPN13DEU as our antigen to: (i) prevent the oligomerization of
UCH37 which lead to unfavorable conformation and (ii) to bias our screening
result to identify exosite binders with higher specificity. To ensure the nanobodies
could be developed as an intrabodies towards proteasome associated UCH37,
we further performed affinity maturation using cell lysate generated from
HEK293RPN11-HTBH, which is a cell line used to prepare UCH37 containing
proteasome, as our antigen. All the antigens that were used in our screening
strategies are either heteromeric or unpurified, hence, negative selection using
UCH37 KO HEK293RPN11-HTBH is incorporated in our screening strategies to
eliminate the risk of enriching nanobodies targeting unwanted protein.
We have adopted the multiplexing in next generation sequencing to
identify the enriched nanobodies using Illumina’s MiSeq paired-end sequencing
(2 x 250 bps), which has been the ideal sequencing platform to sequence the
whole nanobody domain, which consist of around 400 bps. We further
demonstrated that the depth of sequencing offered by next generation
sequencing is crucial in our affinity maturation experiments. Our random
mutagenized library consisted of 17% of unmutated template, which cause the
discovery of positive clones through the low throughput sanger sequencing
difficult. The improve sampling depth has assisted us in identifying the enriched
mutations, which were later revealed to be beneficial. As the sequencing libraries
were prepared through PCR, one of the limitations is that the bias during the
PCR amplification may manifest artificial increase in the number of reads during
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the sequencing and erroneous enrichment ratio. We attempted to correct the
errors by the introducing degenerate codons at the 5’ and 3’ end of our libraries.
These degenerate codons, acting as a unique identified code could decoupled
the error due to bias of the PCR amplification from the enrichment from the
screenings.39 We have inspected our sequencing data with and without the
unique identifiers, and our result showed that the same mutations, that are Q1R,
R33P, H99Y, and A109P were enriched, indicating that the observed enrichment
were genuine (data not shown). From our affinity maturation scheme, we
observed the mutation hotspots at the CDRs which are at or close to the N
terminal, suggesting the anchoring at the N terminal might influence the antigen
recognition of our nanobodies. This prompt us to apply fusion protein at the N
terminal of the identified nanobodies for downstream studies. This is not
surprising in retrospect, as studies have indicated that the fusion protein at the N
terminal of the displayed single chain variable fragment (scFv) and nanobody
could influence the binding affinity towards the antigen. 40,41 Future synthetic
library design could be designed to display the nanobodies on the N terminal of
Aga2p.
We have discovered potential UCH37 binders targeting full length UCH37
with sub-nanomolar affinity. These nanobodies are capable to interact with
UCH37, and UCH37 in complex with RPN13 DEU or RPN13. Limited proteolysis of
the tightest binder, NbAIII.15 in complex with UCH37∙RPN13 DEU suggested the
NbAIII.15 binds at the catalytic domain of UCH37. Detailed structural
investigation is currently in progress to elucidate the binding interactions of
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NbAIII.15 and UCH37∙RPN13DEU at atomic level. We also investigate whether
these UCH37 nanobodies could be utilized as an intracellular tool to probe the
regulation of proteasome-bound UCH37 and our result elucidated that these
intracellularly expressed nanobodies, particular NbAIII.15 immunoprecipitates
UCH37 containing proteasome. Further experiments are being conducted (i) to
determine the biochemical effects of these nanobodies on the activity of UCH37
and (ii) to interrogate the compatibility of using the nanobodies in cellulo or in
vivo.

Materials and Methods
Cell culture
For yeast cells used in the yeast surface display, referred to the cell culture
section in the Material and Methods in Chapter 2.
HEK293 stably expressing RPN11-His6-TEV-biotin tag-His6 (HEK293RPN11-HTBH),
UCH37 KO HEK293RPN11-HTBH, and HEK293FT were cultured in DMEM medium
(Genesee Scientific) supplemented with 10% fetal calf serum (Genesee
Scientific), 100 units/ml penicillin and 100 µg/ml streptomycin at 37 oC in a
humified atmosphere with 5% CO2.

Plasmid and Cloning
His8-MBP-TEV-UCH37 (Isoform 3) in pVP16 vector was obtained from DNASU.
GST-3C-RPN13DEU (or RPN13253-407) was cloned from His10-RPN13 in pET19b,
which was a gift from Joan Conaway & Ronald Conaway (Addgene plasmid #
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19423). 1436 pcDNA Flag HA was a gift from William Sellers (Addgene plasmids
#10792). All PCR amplifications were performed with Phusion® High-Fidelity
DNA polymerase (New England Biolabs). The primers used in this study were
purchased from IDT DNA. All the sequences were verified through Sanger
sequencing.
For bacterial expression of Avi-Ubiquitin1-75 Intein, Avi-UCH37 and Avi-USP30
the Avi-tag were introduced through site-directed insertion. GST-TEV-UCH37
construct was generated by replacing the His8-MBP fragment in the UCH37 in
pVP16 vector with GST fragment (GST from pGEX6P1) through megaprimer
PCR. For bacterial expression of the nanobody, the enriched nanobodies in the
selections were cloned into pET28b (Novagen) at NdeI and XhoI (New England
Biolabs) restriction enzyme sites. The point mutations were introduced into the
nanobody through site-directed mutagenesis using megaprimer PCR. To
generate HaloTag nanobody for mammalian expression, the GGGS 3 nanobody
(in pCT vector) were PCR amplified and inserted into a HaloTag containing
pET28b vector through megaprimer PCR. The HaloTag nanobodies cassetts
were amplified and cloned into pCDNA3 HA FLAG (Addgene #10792) at BamHI
and XhoI (New England Biolabs) restriction enzyme sites.

Protein purification
All protein purifications were performed at 4oC.
Avi-Ubiquitin1-75-propargylamine (AviUb-PA) was synthesized from Avi-Ub 1-75intein. Briefly, Avi-Ub1-75-intein was expressed in E. coli Rosetta (DE3) pLysS
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using 2xYT media. The cells were grown at 37oC to OD 0.6 before induced with
0.5 mM IPTG at 18oC overnight. The cells were lysed in 20 mM sodium
phosphate, pH 6.0, 500 mM NaCl, 1 mM EDTA. The Avi-Ub 1-75-intein was loaded
onto chitin resin (New England Biolabs). The immobilized protein was incubated
with lysis buffer in the presence of 100 mM sodium 2-mercaptoethanesulfonate
(MESNA) (Acros Organic) for 48 hrs at 4 oC to generate Avi-Ub1-75-MESNA
through on-resin cleavage. The Avi-Ub1-75-MESNA (final concentration was 500
µM) was incubated in a buffered solution containing 20 mM Tris, pH 8.0, 10 mM
N-hydroxysuccinimide, 1 M propargylamine (Alfa Aesar) at 37 oC for overnight to
yield AviUb-PA. All the Avi-Ub variants were verified using MALDI-TOF mass
spectrometry (MS).
UCH37 was purified through glutathione affinity chromatography. In short, the
GST-3C-UCH37 was expressed in E. coli BL21 (DE3). The cells were grown at
37oC to OD 0.6 before induced at 20oC with 0.4 mM IPTG for overnight. The
harvested cells were lysed in 50 mM HEPES, pH 7.5, 150 mM NaCl and applied
to glutathione (Genscript) resin. The elution buffer was 50 mM Tris, pH 8.0, 10
mM reduced glutathione. The UCH37 was further purified through anionic
exchange chromatography using MonoQ on an ÄKTA purifier (GE Healthcare).
The equilibrate buffer was 50 mM HEPES, pH 7.5, 0.5 mM TCEP and the elution
buffer was 50 mM HEPES, pH 7.5, 1 M NaCl, 0.5 mM TCEP.
Avi-UCH37·RPN13DEU and UCH37·RPN13DEU complexes was purified through
tandem affinity purification. In brief, His8-MBP-TEV- Avi-UCH37/UCH37 and
GST-3C-RPN13DEU were expressed in E. coli BL21 (DE3). The cells were grown
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at 37oC to OD 0.6 before induced at 20oC with 0.4 mM IPTG for overnight. The
harvested cells were mixed at 1:1 ratio and lysed in 50 mM HEPES, pH 7.5, 150
mM NaCl, 10 mM imidazole. The complexes were purified using nickel (Gold
Biotechnology) affinity chromatography to pull down His-tagged UCH37 and its
binding partners. The complexes were eluted using 50 mM HEPES, 150 mM
NaCl, 300 mM Imidazole, followed by the TEV cleavage reaction to remove the
His8-MBP tag. The resulting complexes were then buffer exchanged into 50 mM
HEPES, pH 7.5, 150 mM NaCl and subjected to glutathione (Genscript) affinity
chromatography to pull down GST-tagged RPN13 DEU and its binding partners.
The complexes were eluted using 50 mM Tris, pH 8.0, 10 mM reduced
glutathione and 3C protease reaction was then carried out to remove the GST
tag. The complexes were further purified through size exclusion chromatography
using a HiLoad Superdex 200 pg on an ÄKTA purifier (GE Healthcare). The
running buffer was 50 mM HEPES, pH 7.5, 50 mM NaCl, 0.5 mM TCEP.
UCH37∙RPN13 complex was purified through tandem affinity purification. In brief,
both His8-MBP-TEV-UCH37 and His10-RPN13 were expressed in E. coli BL21
(DE3). The cells were grown at 37 oC to OD 0.6 before induced at 20oC with 0.4
mM IPTG for overnight. The harvested cells were mixed at 1:1 ratio and lysed in
50 mM HEPES, pH 7.5, 200 mM NaCl, 1 mM EDTA and 1 mM TCEP. The
complex was purified using amylose (New England Biolabs) affinity
chromatography to pull down His8-MBP-TEV-UCH37 and its binding partner. The
complex was eluted with the lysis buffer in the presence of 10 mM maltose,
followed by TEV cleavage reaction to remove His8-MBP tag. The resulting
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complexes were then buffer exchanged into 50 mM HEPES, pH 7.5, 150 mM
NaCl, 10 mM imidazole and subjected to nickel (Gold Biotechnology) affinity
chromatography to pull down GST-tagged RPN13 DEU and its binding partners.
The complexes were eluted using into 50 mM HEPES, pH 7.5, 150 mM NaCl,
300 mM imidazole and was further purified through size exclusion
chromatography using a HiLoad Superdex 200 pg on an ÄKTA purifier (GE
Healthcare). The running buffer was 50 mM HEPES, pH 7.5, 50 mM NaCl, 0.5
mM TCEP.
The His6-HALO-GGGS3-nanobody/nanobody (Nb) variants were purified through
immobilized metal affinity chromatography. The His6-tagged Nbs were expressed
in E. coli BL21 (DE3). The cells were grown at 37oC to OD ~0.6 before induced
at 20oC with 0.4 mM IPTG for overnight. The harvested cells were lysed in 50
mM HEPES, pH 7.5, 300 mM NaCl, 10 mM imidazole and purified using nickel
(GoldBio) affinity chromatography. The elution buffer was 50 mM HEPES, pH
7.5, 300 mM NaCl, 300 mM imidazole. The Nbs were further purified through size
exclusion chromatography using a HiLoad Superdex 75 pg on an ÄKTA purifier
(GE Healthcare). The running buffer was 50 mM HEPES, pH 7.5, 300 mM NaCl,
0.5 mM TCEP.

Generation of biotinylated protein
To prepare biotinylated Ub conjugated to UCH37∙RPN13 DEU (or USP3067-517) ,
the Avi-Ub-PA was biotinylated through BirA reaction before conjugated to
UCH37∙RPN13DEU. Briefly, the Avi-Ub-PA (final concentration was 40 µM) was
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added to a solution containing 10 mM Tris, pH 8.0, 5 mM MgCl2, 2 mM ATP, 150
mM D(+) biotin (Gold Biotechnology), and 0.4 µM BirA at 37 oC until the
biotinylation reaction went to completion (fresh BirA and ATP were provided
every 30 mins). The reaction was verified using MALDI-TOF MS. The 5 µM
biotinylated Ub-PA was incubated with 2.5 µM UCH37∙RPN13 DEU in a buffered
solution containing 50 mM HEPES, pH 7.5, 50 mM NaCl, 1 mM TCEP at room
temperature for 1 hr with gentle rocking. The biotinylated ternary complex was
further purified through size exclusion chromatography using a HiLoad Superdex
200 pg on an ÄKTA purifier (GE Healthcare). The running buffer was 50 mM
HEPES, pH 7.5, 50 mM NaCl, 1 mM TCEP.
To prepare biotinylated UCH37∙RPN13DEU (or USP3067-517) , the AviUCH37∙RPN13DEU was biotinylated using the same BirA reaction conditions,
except the reaction was performed at 4oC for 16 hrs with gentle rocking (fresh
BirA and ATP were added into the reaction mixture in between). The biotinylated
UCH37∙RPN13DEU was further purified through size exclusion chromatography
using a HiLoad Superdex 200 pg on an ÄKTA purifier (GE Healthcare). The
running buffer was 50 mM HEPES, pH 7.5, 50 mM NaCl, 1 mM TCEP. Western
blot was performed using streptavidin, Alexa FluorTM 647 conjugate
(ThermoFisher Scientific) at 1:15000 dilution to validate the biotinylation of
UCH37.
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Construction of the random mutagenized NbAI.1 library
The NbAI.1 gene was randomly mutagenized using Mutazyme II, a commercially
available error prone DNA polymerase (Agilent Technologies) using
pCT_Nb_amp_f and pCT_Nb_amp_r (Table B-3). The mutagenized NbAI.1 gene
library pool was then amplified with the same primers using Phusion ® high
fidelity DNA polymerase (New England Biolabs). To prepare electrocompetent
yeast cells, a 50 ml culture of EBY100 cells were grown to OD 1.5 and treated
with 25 mM DTT for 15 mins. The cells were then harvested, washed and
resuspended in 2 x 150 µl of ice cold 10 mM Tris, pH 7.5, 270 mM sucrose, 2
mM MgCl2. Cells were transformed separately using 1 µg of NheI and BamHI
(New England Biolabs) of digested pCT vector containing NbAI.1 gene and 3 µg
of amplified Nb gene library pool through electroporation. The combined
transformed cells were recovered in YPD media before exchanged into SDCAA
media. Recovered cells were serial diluted and plated in -Trp dropout media for
2-4 days at room temperature to estimate the size of the library.

Next generation sequencing (NGS) sample preparation and analysis
The sequencing library was generated through reduced cycle amplification to add
Illumina adapters to the Nb in two sequential PCR. In the first PCR, the extracted
plasmids were PCR amplified using Nbseq_deg_f and Nbseq_deg_r (Table B-4)
to add in the partial Illumina adapters to the Nb. The PCR cycle conditions were:
98oC for 30 s, followed by 25 cycles of 98oC for 10 s, a temperature gradient of
64 – 68oC for 30 s, 72oC for 30 s, with a final extension of 72oC for 5 mins. PCR
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products was separated through agarose gel electrophoresis where the
amplicons with the correct base pairs were excised and purified. The purified
amplicons were PCR amplified again with reduced amount (0.05 µM) of
Nbseq_N502/N503 and Nbseq_N701 (Table B-4) to add in the full-length
Illumina adapters. The PCR conditions were 98 oC for 30 s, followed by 12 cycles
of 98oC for 10 s, 55oC for 30 s, 72oC for 60 s, with a final extension at 72oC for 5
mins. All PCRs were performed using Phusion ® high fidelity DNA polymerase
(New England Biolabs)
The quantity of Nb amplicon libraries was verified using Qubit dsDNA
HighSensitivity Assay (Life Technologies). The quality of the libraries was
checked using Agilent 2100 Bioanalyzer, and there was no detectable adapter
dimer. The libraries were quantitated using NEBNext Library Quant Kit for
Illumina (New England Biolabs) on Agilent Mx3005P qPCR instrument. The
libraries were pooled with 40% Phi-X library spike-in (Illumina) and sequenced on
Illumina MiSeq using Nano v2-500 cycle kit, with 251 bp paired-end chemistry.
The quality of the sequence data was checked using FastQC. 42 and the average
quality per read for all samples was in a range of a mean Phred score of 37.
For data analysis, the paired-end read were merged using FLASH. 43 The
resulting reads were trimmed by BBDuk translated with SeqKit. 44,45 Downstream
analysis was performed in R. The enrichment ratios of a given variants was
calculated by dividing the normalized Nb frequencies enriched through sorting
over the normalized Nb frequencies presented in the initial error prone NbAI.1
library.
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Selection of Nanobodies (Nbs) against UCH37∙RPN13 DEU
The display of the Nb on the yeast surface was induced by resuspending 10x
diversity of the Nb library in the SGCAA (20 g/L galactose, 6.7 g/L yeast nitrogen
base, 5 g/L casamino acids, 5.4 g/L Na2HPO4, 8.56 g/L NaH2PO4∙H2O) media
supplemented with 100 units/ml penicillin and 100 µg/ml streptomycin at 20 oC.
The induced cells were subjected to washing before and after incubation with
PBSF buffer (0.1% (v/v) BSA in PBS buffer, pH 7.4). The induced cells were
subjected to two subsequent magnetic activated cell sorting (MACS) and two
fluorescent activated cell sorting (FACS) to select Nbs bind to Ub conjugated
UCH37∙RPN13DEU. For MACS, the induced cells were negatively sorted against
DynabeadsTM M-280 Streptavidin (ThermoFisher Scientific) before positively
sorted against Dynabeads coated with biotinylated Ub conjugated
UCH37∙RPN13DEU. All MACS were performed at 4oC for 1-2 hrs. For FACS, the
induced cells were labeled with chicken anti c-Myc (Exalpha biologicals INC) at
1:250 dilution for 30 mins at room temperature. The labeled cells were then
incubated with varied concentration of biotinylated Ub conjugated
UCH37∙RPN13DEU or biotinylated UCH37∙RPN13DEU in complex with NbAI.1 for
30 mins at room temperature before simultaneously labeled with goat anti
chicken IgY (H+L) secondary antibody, Alexa FluorTM 647 and streptavidin, Alexa
FluorTM 488 conjugate (ThermoFisher Scientific) at 1:100 dilution for 15 mins on
ice in a shielded box. Sortings were performed on a BD FACS ARIA II with 488
nm (530/30 band pass collection filter) and 640 nm (670/30 band pass filter)
excitation lasers. At the end of FACS, yeast display plasmids were isolated from
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the enriched clones using the Zymoprep yeast plasmid miniprep kit (Zymo
Research). The enriched clones were identified through Sanger sequencing
using pCT_Nb_amp_r (Table B-3).

Selection of Nanobodies against proteasome associated UCH37
The NbAI.1 library was cultured, induced, and washed as previously described.
The induced yeast cells were first labeled with chicken anti c-Myc at 1:250
dilution for 30 mins at room temperature. This was followed by the incubation of
the cells with clarified cell lysate of the HEK293 RPN11-HTBH in a buffered solution
containing 50 mM HEPES, pH 7.5, 50 mM NaCl, 5 mM MgCl 2, 2 mM ATP, 10%
glycerol for 45 mins at room temperature. The cells were then similarly labeled
with the secondary antibodies and sorted through FACS as mentioned in the
Selection of nanobodies against UCH37∙RPN13 DEU. For negative sorting, cell
lysate of UCH37 KO HEK293TRPN11-HTBH was used as the antigen. The plasmids
containing gene of the enriched clones was extracted through Zymoprep yeast
plasmid miniprep kit and submitted for Sanger sequencing or used in the
preparation of NGS sequencing library.

Validation of the enriched mutations
Yeast cells were transformed with the plasmid encoded for the nanobodies with
enriched mutations (referred to Yeast growth and induction in the Materials and
Methods in Chapter 2). The yeast cells were cultured, induced, and washed as
previously described. For validation, the cells were incubated with the cell lysate
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generated from HEK293RPN11-HTBH or UCH37 KO HEK293RPN11-HTBH in a buffered
solution containing 50 mM HEPES, pH 7.5, 50 mM NaCl, 5 mM MgCl2, 2 mM
ATP, 10% glycerol for 45 mins, at room temperature with gentle rocking (or with
biotinylated UCH37∙RPN13DEU in PBS for 30 mins). The cells were then similarly
labeled with primary and secondary antibodies as mentioned in the Selection of
nanobodies against proteasome associated UCH37 before subjected to flow
cytometry analysis on a BD LSR Fortessa X20.

In vitro pull down assay
HaloTag nanobodies were incubated with the recombinantly expressed UCH37
or UCH37∙RPN13 for 1 hr at room temperature with gentle rocking in a buffered
solution of 50 mM HEPES, pH 7.5, 150 mM NaCl, 0.05% IGEPAL. The mixtures
were then incubated with pre-equilibrated HaloLinkTM resin (Promega) for 30
mins at room temperature with gentle rocking. The immunoprecipitated proteins
were extensively washed and eluted using SDS loading dye at 95 oC for 10 mins
before subjected to SDS-PAGE analysis.

Surface plasmon resonance (SPR) measurement
The surface plasmon resonance experiments were performed using a BIACORE
T200 (GE Healthcare) equipped with a Series S Sensor Chip NTA. The surfaces
of the flow cells were conditioned using 350 mM EDTA for 1 min at a flow rate of
10 µl/min before injecting 0.5 mM NiSO4 for 1 min at 10 µl/min. The purified His6Nb (15 kDa) was then injected for 2 mins at 10 µl/min and immobilized on the Ni-
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NTA surface at a density of approximately 30 response units (RU). Single cycle
kinetic titration experiments were performed by injecting purified UCH37 (37 kDa)
at increasing concentration in 50 mM HEPES, pH 7.5, 50 mM NaCl, 50 µM
EDTA, 0.005% (w/v) TWEEN 20 at a flow rate of 30 µl/min with a 300 s contact
time and 900 s dissociation time. The flow cell surfaces were regenerated using
2 pulses of 350 mM EDTA for 2 min at a flow rate of 10 µl/min. The sensorgrams
were double referenced before analyzed using BIAevaluation (GE Healthcare).
The association and dissociation rate constant, ka and kd, were determined from
the direct curve fitting to a 1:1 binding model; the dissociation equilibrium
constant, KD, was calculated from kd/ka. All experiments were performed at 25oC.

Size exclusion chromatograph-multi angle light scattering (SEC-MALS)
analysis
SEC-MALS was performed in a TSKgel G3000SWXL column (TOSOH
Biosciences) on a Agilent 1260 Infinity HPLC system (Agilent Technologies)
coupled to a MALS detector, DAWN HELEOS II (Wyatt Technology) and a
refractive index detector, Optilab T-rEX (Wyatt Technology). For nanobody
complexes, nanobodies were incubated with UCH37∙RPN13 DEU on ice for 10
mins before the analysis. The flow rate was 0.5 ml/ min and the mobile phase
was 50 mM sodium phosphate, pH 6.5, 400 mM sodium perchlorate, 10%
isopropanol. Data was analyzed using Astra (Wyatt Technology) and the molar
masses of the complexes were determined by the Zimm fit model. All the
experiments were performed at room temperature.
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Limited proteolysis analysis
Limited proteolysis of UCH37∙RPN13DEU and NbAIII.15 in complex with
UCH37∙RPN13DEU (around 4.5 µg at 1.1 µg/µl) were performed in 50 mM sodium
phosphate, pH 8.0 with LysC at 1:40 g/g ratio for 37 oC for 15 mins. Here,
NbAIII.15 was incubated with UCH37∙RPN13DEU on ice at 2:1 ratio for 10 mins
before digestion. For quenching, 1 µl of the reaction mixture was added into 10 µl
of saturated α-Cyano-4-hydroxycinnamic acid (CHCA) (Sigma-Aldrich) in 30%
acetonitrile, 0.1% TFA and 1 µl of the quenched sample were spotted on a 96ground steel MALDI target plate. Data was acquired on a Bruker MALDI-TOF
MicroFlex or UltrafleXtreme in linear positive ion mode with 20% laser power and
500 shots were collected per spectrum. Data processing was performed using
FlexAnalysis software (Bruker). The identities of the proteolysis fragments were
determined using ProteinProspector.

Transient transfection
The vectors used in the transient transfection were generated by the cloning of
the 1436 pCDNA3 Flag HA (1436 pcDNA Flag HA was a gift from William Sellers
(Addgene plasmids #10792)). Transient transfections of mammalian cells were
performed using XfectTM transfection reagent (Takara Bio) according to the
manufacturer’s protocol and scaling recommendation. Briefly, HEK293FT were
grown to 35% confluency. Plasmid DNA was incubated with the Xfect polymer at
room temperature for at least 10 mins before added drop wise to the adhered
cells. The cells were incubated with the complete growth media containing DNA
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nanoparticles for 4 hrs before replacing it with fresh media and further incubated
for 48 hrs and the cells were prepared for downstream analysis.

Immunoprecipitation for western blotting
10 cm2 dishes of HEK293FT cells were grown and transfected with respective
HaloTag Nb as described above. The harvested cells were lysed in 50 mM
HEPES, pH 7.5, 50 mM NaCl, 5 mM MgCl2, 2 mM ATP, 1 mM DTT, 10% glycerol
before incubated with HaloLinkTM Resin (Promega Corporation) for 30 mins at
room temperature. The immunoprecipitated proteins was washed extensively
with 50 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 2 mM ATP, 1 mM DTT,
0.05% IGEPAL prior to elution using SDS loading dye at 95 oC for 10 mins.
Western blot analysis were performed using the following antibodies: rabbit antiUCH37 [EPR4896] (abcam), rabbit anti-ADRM1 (D9Z1U) (Cell Signaling
Technology), rabbit anti-PSMD14 [EPR4258] (abcam), rabbit anti-PSMC1
(ab3317) (abcam) and mouse anti-PSMB7 (R&D systems) at 1:1000 dilution.
IRDye® 680RD goat anti-rabbit and IRDye® 800CW goat anti-mouse (LI-COR
Biosciences) were used as the secondary antibodies at 1:15000 dilution.

Immunoprecipitation for mass-spectrometry
15 cm2 dishes of HEK293FT cells were grown and transfected with respective
HaloTag nanobodies as described above. The harvested cells were lysed and
immunoprecipitated similarly as described above. The immunoprecipitated
proteins was washed extensively with 50 mM HEPES, pH 7.5, 150 mM NaCl, 5
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mM MgCl2, 2 mM ATP, 1 mM DTT before eluted with 8M urea in 25 mM NH4CO3
for 1 hr at room temperature. The eluted proteins were reduced with 10 mM DTT
at 37oC for 1 hr and alkylated using 25 mM iodoacetamide (Sigma-Aldrich) in 25
mM NH4CO3 at room temperature for 1 hr in the dark before subjected to in
solution trypsin digest using sequencing grade modified trypsin (Promega
Corporation) for overnight at 37oC. Tryptic digests were desalted with Sep-Pak
C18 cartridge (Waters) and separated by a homemade fused silica capillary
column (75 μm x 150 mm) packed with C-18 resin (120A, 1.9 μm, Dr. Maisch
HPLC GmbH) with the EASY-nLC 1000 nano-HPLC system (ThermoFisher
Scientific), which was coupled with the Orbitrap Fusion Tribrid mass
spectrometer. Peptides were eluted by applying a 90 min gradient elution at 300
nl/min: 5% to 40% buffer B over 40 min, 40% to 60% buffer B over 20 min, and
60-95% buffer B over 10 min (solvent A: 0.1% formic acid (FA) in water, solvent
B: 0.1% FA in ACN). Full MS scans were acquired at a resolution of 120000
between 350-2000 m/z. Collision-induced dissociation (CID) was induced on the
twelve most abundant ions per full MS scan using an isolation width of 20 ppm.
Fragmented precursor ions were allowed one repeated MS/MS analysis and the
excluded for 15 s.
LC-MS/MS Data were searched against human proteome database in UniProt by
using the Proteome Discoverer 2.4 with the SEQUEST HT search engine. The
search parameters were: peptides mass tolerance of 10 ppm; MS/MS tolerance
of 0.6 Da; two missed cleavages allowed; Carbamidomethylation of cysteine was
a fixed modification. Oxidation of methionine and carbamylation of lysine,
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arginine and peptide N-terminus were used as variable modifications. Label‐free
quantitation was performed using the Minora algorithm of Proteome Discoverer
2.4. The following parameters were used: Protein abundances were based on
peptide peak area, top-3 peptides will be used for quantification. Protein
abundance ratios were based on pairwise ratios. Student’s t-test will be used and
differences were considered as significant at the p < 0.05 level.
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CHAPTER 4
DEVELOP AN INTRACELLULAR PROBE FOR PROTEASOME-ASSOCIATED
UCH37
Abstract
As a main component in the ubiquitin proteasome system, the proteasome is
subjected to multilayer regulations. One of the possible regulations is the
recruitment of proteasomal subunits. UCH37 is a proteasome associateddeubiquitinase which is sub-stoichiometry to and interact dynamically with the
proteasome. Here, we have engineered a nanobody as a probe for intracellular
imaging of proteasome-bound UCH37. The nanobody does not affect the
enzymatic activity of the proteasomal UCH37, which enable the detection the
enzyme inside living cells in real time, with minimal perturbation towards the
proteasome-associated UCH37. Furthermore, we improved the sensitivity of the
probe by converting the nanobody to a conditionally stable variants to visualize
proteasome-bound UCH37 close to endogenous level.
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Introduction
26S proteasome is an important component in the ubiquitin dependent
proteolysis, which is responsible for around 80% of the protein degradation in
eukaryotes.1 In the ubiquitin proteasome system (UPS), the substrates to be
degraded are ubiquitinated, mainly with Lys48- linked ubiquitin chains, which
would triggered the recruitment of 26S proteasome. The 26S proteasome is a
macromolecular complex, consists of around 30 proteins subunits and could be
categorized into two components: the 19S regulatory particle (19S RP) and 20S
core particle (20S CP). The 19S RP contains the ubiquitin protein conjugates
recognition or editing elements and an AAA+ ATPase which unfold the
substrates. The ATPases also translocate the unfolded substrates through a
gated channel to the barrel-shaped 20S CP with a proteolytic core for
proteolysis.2 The ubiquitin proteasome system involves in a plethora biological
events, such as cell cycle, protein qualify control and signal transduction.
To ensure efficient ubiquitin-dependent proteolysis, the proteasome is
tightly regulated at multi-level, from the expression level of the proteasome
subunits, post translational modifications and the assembly of the proteasome
complex.3 Nonetheless, the recruitment of the 19S RP subunits which are
responsible for the ubiquitin protein conjugates recognition and deubiquitination
are still poorly understood. It has been well established that the binding of the
ubiquitin protein conjugate does not necessary lead to substrate degradation by
proteasome.4 Hence, understanding the role of independent ubiquitin interacting
proteasome associated subunits and how they contribute to proteasomal
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degradation are crucial. First, why there are different ubiquitin receptors and
deubiquitinases on the 19S RP, if they are performing the similar tasks? To what
extent there is functional redundancy across these ubiquitin interacting proteins?
There are two main proteasomal ubiquitin receptors on the proteasome: RPN10
and RPN13. Study has demonstrated that while RPN10 is the main ubiquitin
receptors for ubiquitinated substrates, RPN13 might show preference towards
the UBL domain of the ubiquitin shuttling factors.5 This finding suggests that the
presence of multiple ubiquitin receptors on the 19S RP would allow the versatile
detection of ubiquitinated substrates with different topologies by the proteasome.
Nonetheless, the deletion of either RPN10 or RPN13 only result in mild
impairment, suggesting the role of RPN10 and RPN13 maybe redundant in vivo.6
Similarly, there are several proteasome-associated deubiquitinases
located at the 19S RP; they are USP14, UCH37 and RPN11. Both USP14 and
UCH37 are cysteine protease while RPN11 is a zinc metalloprotease. 7 Further
biochemical studies have elucidated that both USP14 and RPN11 break down
the ubiquitin chain en bloc, with RPN11 mainly hydrolyzes the isopeptide bond
between the proximal ubiquitin and the substrate.8 On the other hand, UCH37 is
reported to remove ubiquitin from the distal tips and is shown to preferentially
hydrolyzed branched ubiquitin chains.9
Intriguingly, quantitative mass spectrometry analyses has suggested that
in contrast to RPN11, which is a constitutive proteasomal subunit, both USP14
and UCH37 exist at a sub-stoichiometric level, and interact with the 19S RP
dynamically.10,11 In addition, these deubiquitinases are reported to exist in
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proteasome-free state.12 It has been reported that the activity of the proteasome
could be regulated by the assembly of proteasome with different subunits. 13,14,15
Are the labile interactions of USP14 or UCH37 with proteasome one of the
regulation mechanism in the ubiquitin proteasome system? What is the
recruitment pattern of USP14 and UCH37 on the proteasome inside a living cell?
What are the triggers for the dynamic (dis)incorporation of USP14 and UCH37 on
the proteasome?
Physiologically, the knockdown of RPN11 inhibits the degradation of
cellular protein, which clearly delineate the role of RPN11 in the ubiquitin
dependent proteolysis.12,16 On the other hand, the knockdown or either USP14 or
UCH37 has limited effect on the degradation rate, but the knockdown of both
USP14 and UCH37 inhibit the protein degradation. 12 Does this suggest there are
certain degree of functional redundancy between USP14 and UCH37? However,
studies has elucidated that cells transiently express inactive USP14 and UCH37
lead to accumulation of distinct ubiquitinated substrates, suggesting these
deubiquitinases might be substrates selective.17
We have discovered a nanobody specific towards proteasome-associated
UCH37 and we hypothesize that the nanobody could be utilized as an
intracellular probe to tackle the unknowns surrounding the proteasomal UCH37
as described above. For example, the nanobody could be fused to a fluorescent
tag to visualize the localization of UCH37 on the proteasome and give insights
into the dynamics of proteasome bound UCH37 under different biological events,
such as stress or during cell cycle using fluorescent microscopy (Figure 4-
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1A).18,19 Furthermore, we could engineer a nanobody with enzyme-catalyzed
proximity labeling, such as TurboID to study the substrate of UCH37 (Figure 41B).20,21 UCH37 is a potential therapeutic target in cancer; a nanobody which
inhibit the catalytic activity of UCH37 could be developed to investigate the
physiological role of UCH37 in a disease model (Figure 4-1C).22,23

Figure 4-1: Potential applications of nanobodies.
Scheme showing the potential applications of nanobody to (A) visualize the
recruitment of proteasome bound UCH37, (B) identify the potential substrates of
UCH37, and (C) validate the functional role in a disease model.

Here, we showed that our engineered nanobodies does not interfere with
the enzymatic activities of proteasomal UCH37. We further converted the
nanobody to a conditionally stable nanobody under an inducible promoter; by
removing the unbound nanobody, we reduce the background signal and permit
the visualization of the proteasome bound UCH37 close to endogenous level. 24
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Result
UCH37 nanobodies do not inhibit proteasome-associated UCH37
In the previous chapter, we have discovered two distinct UCH37
nanobodies, which are NbAI.1 and NbAII.1 using ubiquitin conjugated
UCH37∙RPN13DEU at the catalytic Cys and UCH37∙RPN13DEU as antigen. How
do the different nanobodies affect the activities of UCH37? Our group has
demonstrated that UCH37 exclusively hydrolyzes Lys48 linked branched
ubiquitin chains.9 UCH37 debranching of a high molecular weight ubiquitin chains
consisting of Lys6 and Lys48 branched linkages (K6/K48 HMW ubiquitin chain) is
followed through SDS-PAGE analysis (Figure 4-2A and B). Our result showed
that both nanobodies effectively inhibit the debranching activities of UCH37, with
an IC50 in the low micromolar range, which is the concentration of UCH37 used in
the assay (Figure 4-2C and Figure B-8).
We further investigated the inhibitory effect of NbAI.1 and NbAII.1 on the
debranching activity of UCH37∙RPN13. We observed that NbAI.1 effectively
inhibits the activity of UCH37∙RPN13, while NbAII.1 did not (Figure 4-2D and
Table 4-1 and Figure B-9). It is not surprising, as we had demonstrated that
NbAII.1 does not complex with UCH37∙RPN13 DEU productively. Studies have
shown that free UCH37 and UCH37∙RPN13 adopt different conformation; our
result indicated that while NbAII.1 might bind to free UCH37, it does not
recognize or has low affinity towards UCH37∙RPN13 where UCH37 has a
different conformation.25,26 At the highest concentration in the assay, which
concentration was 20 times in excess to the concentration of UCH37∙RPN13,
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NbAII.1 only achieved 85% of inhibition (Figure B-10). We proceeded to study
the effect of the derivatives of NbAI.1, which are NbAIII.15 and NbAIII.16 towards
the debranching activities of UCH37∙RPN13. These NbAI.1 derivatives which are
identified using non purified UCH37 containing proteasome as antigen, also
inhibit UCH37∙RPN13 within the same order of magnitude with NbAI.1 (Figure 42D and Table 4-1 and Figure B-9).

Figure 4-2: Investigate the effect of nanobodies on the activities of UCH37
and UCH37∙RPN13
(A) Scheme of the UCH37 or UCH37∙RPN13 cleavage assay using branched
ubiquitin chains. (B) Representative gel for the cleavage assay using high
molecular weight Lys6-/ Lys48- linked branched ubiquitin chains by UCH37
against a concentration gradient of NbAI.1. (C) Normalized inhibition of the
debranching activities of UCH37 treated with NbAI.1 and NbAII.1. Error bars
represent the standard error of two biological replicates. (D) Normalized inhibition
of the debranching activities of UCH37∙RPN13 treated with NbAI.1, NbAII.1,
NbAIII.15 and NbAIII.16. Error bars represent the standard error of two biological
replicates.
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Table 4-1: IC50 of nanobodies towards UCH37∙RPN13
Nb
AI.1
AII.1
AIII.15
AIII.16

IC50 (uM)
0.94±0.09
8±1
2.5±0.7
1±4

Next, we would like to check whether our nanobodies would inhibit the
debranching activities of proteasome-associated UCH37. Using a HEK293 cell
line stably expressing RPN11-His6-TEV-Biotin-His6 (HEK293RPN11-HTBH), we have
purified USP14 depleted proteasome through affinity purification, hence, the only
proteasome-associated deubiquitinase on the purified proteasome that is
capable of cleaving ubiquitin chains is UCH37 (Figure B-11). In parallel, we
prepared biotinylated HMW K6/K48 ubiquitin chains with spike-in biotinylated
ubiquitin to improve the sensitivity of the assay. Astonishingly, all of our
nanobodies do not show significant inhibition towards proteasome-bound UCH37
in hydrolyzing HMW K6/K48 branched ubiquitin chains (Figure 4-3A). Even with
NbAIII.15, which is demonstrated to interact with proteasome-associated UCH37,
we only observed partial inhibition at high concentration, which is at 1000 times
in excess of proteasomal UCH37 (Figure 4-3B). Further inhibition kinetics
assays using UCH37∙RPN13 and proteasomal UCH37 are crucial to understand
the observed discrepancy in the inhibitory effect of our nanobodies towards
UCH37 in different stages.
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Figure 4-3: Branched polyubiquitin cleavage assay by proteasome
associated UCH37
Representative Western blot for the cleavage assay using biotinylated high
molecular weight Lys6- /Lys48- linked branched ubiquitin chain by proteasome
associated UCH37 (A) treated with NbAI.1, NbAII.1, NbAIII.15 and NbAIII.16 and
(B) treated with NbAIII.15 against a concentration gradient.

Develop conditionally stable proteasome-associated UCH37 nanobody
Our result indicated that the nanobodies bound proteasome associated
UCH37 retains its enzymatic activity in vitro. We decided to develop our
nanobodies as an intracellular imaging probe to study the regulation of the
proteasome-associated UCH37. Here, we focused on NbAIII.15, which has been
demonstrated to interacts with UCH37 containing proteasome in a native cellular
context through immunoprecipitation. One of the major challenges of using the
genetically expressed nanobodies is that their stabilities are independent of their
antigens. As a result, it has been difficult to monitor the dynamic of the
127

nonmembrane associated protein which is ubiquitous in nucleus and cytoplasm.
Nonetheless, there are studies reported the level of certain fluorescently labeled
nanobodies, or chromobodies, are influenced by the expression level of their
antigen, suggesting possible antigen-mediated stabilization effect by
chromobodies. Further sensitizing the stability of the nanobody to the antigen
level would allow the tracking of the dynamics endogenous proteins under
different biological events, such as during cell cycles or upon treatment. In
addition to accelerate the protein turnover by introducing certain amino acid
residues to induce proteasomal degradation based on N-end rule, studies has
shown that certain mutations could be readily transferred on the framework of the
nanobodies to cause the nanobodies to be conditionally stable. 19 Those
mutations are S70R, C92Y, Q105H, and S113F (according to the Chothia
numbering) would destabilize the nanobodies in the absence of their
antigens.24,27,28 It was also demonstrated that these conditionally stable
nanobodies are being degraded through the ubiquitin proteasome system.
We would like to check whether the nanobodies destabilization technique
is applicable for NbAIII.15. Here, we prepared NbAIII.15 variants containing
different combinations of the destabilizing mutations (S70R, C90Y, Q113H and
S121F according to the amino acid sequences of NbAIII.15) (Figure 4-4A). The
stabilities of the NbAIII.15 variants in HEK293FT and UCH37 KO HEK293FT
cells were accessed semi-quantitatively through Western blot (Figure 4-4B and
Figure B-12). Overall, we observed that the transiently expressed NbAIII.15
variants have decrease expression level compare to their wild type counterpart in

128

both WT and UCH37 KO HEK293FT cells, ranging from 10-30% of the
expression of NbAIII.15 (Figure 4-4C and D). However, when we compared the
ratio of expression of these nanobodies variants in the UCH37 KO cells to the
WT, we discovered that the protein level of the nanobodies are higher in the
UCH37 KO cells (Figure 4-4E). This result contradicts our hypothesis, as we
expected the quantities of the nanobodies containing destabilizing mutations are
lower in the absence of UCH37. We reasoned that since UCH37 plays a crucial
role in regulating the proteasomal degradation, the protein turnover of the
nanobodies expressed in the UCH37 KO cells could be suppressed and
comparison of the nanobodies level between the WT and UCH37 KO cells could
be misleading.
Here, we decided to perform a rescue experiment. We either cotransfected the UCH37 KO cells with NbAIII.15 variants and UCH37 or
transfected the UCH37 KO cells with just NbAIII.15 variants. The expression
level of NbAIII.15 variants under both conditions were then compared (Figure 45A and Figure B-13). We observed that for most variants showed an
approximately 5 folds of induction in the presence of UCH37 (Figure 4-5B). Next,
we questioned whether the introduced mutations would affect the interactions of
NbAIII.15 with proteasome associated UCH37. Immunoprecipitations using
transiently expressed conditionally stable NbAIII.15 were performed. Same as
NbAIII.15, these variants are capable to immunoprecipitated with proteasome
associated UCH37 and other proteasomal subunits (Figure 4-6). We decided to
focus on NbAIII.15 S70R/S121F as our conditionally stable nanobody for our
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downstream experiments. In addition, we performed the similar rescue
experiment using NbCtrl and NbCtrl S70R/S121F. Western blot showed that the
fold of induction of the NbCtrl S70R/S121F is around 2-fold, suggesting that it
was not sensitive to the expression of UCH37 (Figure B-14). This further
validates that the NbAIII.15 S70R/S121F is conditionally stabilized by UCH37.

Figure 4-4: Conditionally stable NbAIII.15 in WT and UCH37 KO HEK293FT
cells
(A) Crystal structure of nanobody (PDB ID: 5VNV) with the reported destabilizing
mutations at S70R, C95Y, Q113H, S121F. The CDRs are highlighted in color
(Green for CDR1, pink for CDR2, and blue for CDR3). (B) Representative
Western blot showing the protein level of NbAIII.15 variants in the WT and
UCH37 KO HEK293FT cell lysates. Expression level of NbAIII.15 variants
containing destabilized mutations normalized to NbAIII.15 in (C) WT and (D)
UCH37 KO HEK293FT cells. Error bars represent the standard error of two
biological replicates. (E) Fold of induction of NbAIII.15 variants in WT HEK293FT
cells compare to UCH37 KO HEK293FT cells. Error bars represent the standard
error of two biological replicates.
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Figure 4-5: Conditionally stable NbAIII.15 in UCH37 KO HEK293FT cells
without and with ectopically expressed UCH37
(A) Representative Western blot of the cell lysates and (B) fold of induction of
NbAIII.15 variants in UCH37 KO HEK293FT cells without and with
overexpressed UCH37. Error bars represent the standard error of two biological
replicates.

Figure 4-6: Immunoprecipitation of endogenous
UCH37 by intracellularly expressed
conditionally stably nanobodies.
Representative Western blots showing the
transient expression of nanobodies and the
immunoprecipitation of UCH37, RPN13, RPN11,
and RPT2, which are the 19S RP subunits and
20βs, which is the 20S CP subunits by
intracellularly expressed NbAIII.15 variants.
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Discussion and Future Directions
In Chapter 3, we have identified nanobodies specific towards proteasome
associated UCH37. In this study, we performed a detailed biochemical
characterization of the nanobodies. UCH37 is reported to preferentially hydrolyze
the Lys48 linked branched ubiquitin chains; we showed that the nanobodies
display varied inhibitory effect towards the debranching activity of the UCH37 in
different complex. Although most nanobodies inhibit the UCH37∙RPN13 with an
IC50 at low micromolar range, they could not inhibit the proteasome-associated
UCH37. We have established that the nanobodies bind at the exosite of
UCH37∙RPN13DEU. One of the possible reasons is the recruitment of
UCH37∙RPN13 to proteasome modulates or sterically blocks the epitope
recognized by the nanobodies. Detailed structural analysis is needed to explain
the observed discrepancy in the inhibitory effect of UCH37∙RPN13 and
proteasomal UCH37.
As the nanobodies do not affect the debranching activities of proteasomal
UCH37 in vitro, they could be developed as an imaging tool to probe the
proteasome-bound UCH37 with minimal perturbation towards its catalytic activity.
The major technique in visualizing the UCH37 is through immunofluorescence,
which requires cell fixation and is prone to the introduction of artefacts. While
another common tagging practices is the generation of UCH37 fused to
fluorescent protein, our group has shown that the N and C terminal of UCH37 are
important in the activity of UCH37.29,30 Here, using nanobodies targeting UCH37
could circumvent these issues; it also permits live cell imaging, which is crucial to
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study the dynamic recruitment of UCH37. We do recognize one of the potential
pitfalls is the overexpression of the ectopically expressed nanobodies, which may
complicate the detection of the localization of UCH37 on the proteasome. We
have further engineered our most potent proteasome-associated UCH37
nanobody, NbAIII.15 to a conditionally stable nanobody.
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Here, the conditionally

stable NbAIII.15 (csAIII.15) is constantly destabilized unless it is recognized by
UCH37. csAIII.15 has low expression in cellulo, which might facilitate the
detection of proteasomal UCH37 at endogenous level. We also verified that
csAIII.15 interacted with proteasome associated UCH37.
Generation of cell line stably expressing Halo-csAIII.15 under inducible
promoter is now underway to further control the expression of the imaging
probe.31 Here, we proposed to label the induced csNbAIII.15 with the cellpermeable HaloTag TAMRA ligand. Simultaneously, we would label the
proteasome by treating the cells with a proteasome activity-based probe,
Me4Bodipy-Ahx3-L3-VS, which targets the β subunits of the 20S CP (Figure 47).32 Colocalization analysis would be performed to investigate the recruitment of
UCH37 on proteasome.

Figure 4-7: Strategy to visualize proteasomal UCH37 and 20S CP
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Materials and Methods
Plasmid and cloning
His8-MBP-TEV-UCH37 (Isoform 3) in pVP16 vector was obtained from DNASU.
His10-RPN13 in pET19b was a gift from Joan Conaway & Ronald Conaway
(Addgene plasmid # 19423). All PCR amplifications were performed with
Phusion® High-Fidelity DNA polymerase (New England Biolabs). The primers
used in this study were purchased from IDT DNA. All the sequences were
verified through Sanger sequencing. The cloning of His 6-nanobodies and HAFLAG-HaloTag-nanobodies were described in the Materials and Methods in
Chapter 3. The point mutations were introduced into the nanobody through sitedirected mutagenesis using megaprimer PCR.

Cell culture
HEK293 stably expressing RPN11-His6-TEV-biotin tag-His6 (HEK293RPN11-HTBH),
HEK293FT and UCH37 KO HEK293FT were cultured in DMEM medium
(Genesee Scientific) supplemented with 10% fetal calf serum (Genesee
Scientific), 100 units/ml penicillin and 100 µg/ml streptomycin at 37 oC in a
humified atmosphere with 5% CO2.

Protein purification
All protein purifications were performed at 4oC. For the purification of UCH37,
UCH37∙RPN13 and His6-nanobodies, refer to the Materials and Methods in
Chapter 3.
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To prepare K6/K48 linked high molecular weight (HMW) ubiquitin chains, 0.5 mM
Ub were reacted with 0.2 µM E1, 2 µM UbcH7, 1 µM NleL in a buffered solution
containing 40 mM Tris, pH 8.0, 100 mM NaCl, 10 mM MgCl 2, 10 mM ATP, 6 mM
DTT at 37oC overnight. To prepare biotinylated K6/K48 linked HMW chains, 2
mM Ub were reacted with 0.2 µM E1, 2 µM UbcH7, 1 µM NleL in a buffered
solution containing 40 mM Tris, pH 8.0, 100 mM NaCl, 10 mM MgCl 2, 10 mM
ATP, 6 mM DTT at 37oC for 3 hrs before spiking in 20 µM of biotinylated Ub (The
preparation of the biotinylated Ub was described in the Materials and Methods in
Chapter 2). The chain synthesis reactions was further continued for overnight.
The ubiquitination reactions were quenched with 10 mM DTT in 50 mM NH 4OAc,
pH 4.4 solution for at least 30 mins. The HMW chains was further purified
through cationic exchange chromatography using MonoS on an ÄKTA purifier
(GE Healthcare). The equilibrate buffer was 50 mM NH4OAc, pH 4.4, 100 mM
NaCl and the elution buffer was 50 mM NH4OAc, pH 4.4, 1 M NaCl. For the
biotinylated Ub chain, Western blot was performed using streptavidin, Alexa
FluorTM 647 conjugate (ThermoFisher Scientific) at 1:15000 dilution to confirm
the generation of biotinylated HMW chains.
USP14 depleted 26S proteasome was purified through affinity purification from
HEK293 cells stably expressing RPN11-His6-TEV-biotin tag-His6 (HEK293RPN11HTBH).

Twenty 15 cm2 dishes of HEK293RPN11-HTBH cells were cultured, harvested

and lysed in 50 mM HEPES, pH 7.5, 50 mM NaCl, 5 mM MgCl 2, 2 mM ATP, 1
mM DTT, 10% glycerol. The HTBH-tagged RPN11 containing proteasome was
immobilized for overnight at 4oC on streptavidin agarose resin (Genscript). The
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immobilized proteasome was washed extensively to remove USP14 with 40 mM
HEPES, pH 7.5, 200 mM NaCl, 5 mM MgCl2, 2 mM ATP, 1 mM DTT, 10%
glycerol before eluted by treating the resin with 2 µM TEV enzyme for 1.5 hrs at
room temperature. The eluted proteasome was stored in 40 mM HEPES, pH 7.5,
200 mM NaCl, 5 mM MgCl2, 2 mM ATP, 10% glycerol. Western blot was
performed to investigate the composition of the purified proteasome using the
following antibodies: rabbit anti-UCH37 [EPR4896] (abcam), rabbit anti-ADRM1
(D9Z1U) (Cell Signaling Technology), rabbit anti-USP14 (D8Q6S) (Cell Signaling
Technology), rabbit anti-PSMD14 [EPR4258] (abcam) and mouse anti-PSMB7
(R&D systems) at 1:1000 dilution. IRDye® 680RD goat anti-rabbit and IRDye®
800CW goat anti-mouse (LI-COR Biosciences) were used as the secondary
antibodies at 1:15000 dilution. Especially, western blot against rabbit anti USP14
was to verify the absence of USP14 from the purified proteasome. The activities
of the 20 S proteasome subunit and the proteasome associated deubiquitinase
were verified using fluoregenic proteasome substrate, suc-LLVY-AMC (Boston
Biochem) and fluoregenic ubiquitin hydrolase substrate, Ub-AMC (Boston
Biochem).

Deubiquitinase assay
For the UCH37 and UCH37∙RPN13 cleavage assay, 1 µM of the enzyme was
pre-incubated with nanobody at a concentration gradient in a buffered solution of
50 mM HEPES, pH 7.5, 50 mM NaCl, 3 mM GSH before reacted with 0.3 mg/ml
HWM K6/K48- linked ubiquitin chains for 30 mins at 37 oC. The activity of the
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UCH37 and UCH37∙RPN13 in the presence of nanobody was accessed by gel
densitometry. Gels were stained with SYPROTM Ruby and scanned on a
Typhoon FLA 9500 (GE Healthcare). Data analysis was performed on Image
Studio Lite (LI-COR Biosciences). The IC50 was determined from the direct fitting
to a dose response model on Origin.
For the proteasome-associated UCH37 cleavage assay, USP14 depleted
proteasome (final concentration was 40 nM) were incubated with serial diluted
Nb for 1 hr at 37oC before reacted with 0.3 mg/ ml of biotinylated K6/K48 HWM
Ub chains for 3 hrs at 37oC in a buffered solution containing 50 mM HEPES, pH
7.5, 50 mM NaCl, 5 mM MgCl2, 2 mM ATP, 3 mM GSH. The reactions were
quenched by SDS loading dye prior to western blot analysis using streptavidin,
Alexa FluorTM 647 conjugate (ThermoFisher Scientific) at 1:15000 dilution. Data
acquisition and analysis was performed on Image Studio Lite (LI-COR
Biosciences).

Transient transfection
Transient transfections of mammalian cells were performed using Xfect TM
transfection reagent (Takara Bio) according to the manufacturer’s protocol and
scaling recommendation. Briefly, HEK293FT were grown to 35% confluency.
Plasmid DNA was incubated with the Xfect polymer at room temperature for at
least 10 mins before added drop wise to the adhered cells. The cells were
incubated with the complete growth media containing DNA nanoparticles for 4
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hrs before replacing it with fresh media and further incubated for 48 hrs and the
cells were prepared for downstream analysis.

Analysis for conditionally stable nanobodies
12 well plates of HEK293FT and UCH37 KO HEK293FT cells were grown and
transfected with respective conditionally stable Nbs as described above. The
cells were harvested and lysed in RIPA buffer. Western blot analysis was
performed using chicken anti-FLAG (Exalpha Biologicals) at 1:5000 dilution and
rabbit anti-β-actin (ab8827) (Abcam) at 1:3000 dilution. Goat anti chicken IgY
(H+L) secondary antibody, Alexa FluorTM 647 (ThermoFisher Scientific) and
IRDye® 800CW goat anti-rabbit (LI-COR Biosciences) were used as the
secondary antibodies at 1:15000 dilution. Data acquisition and analysis was
performed on Image Studio Lite (LI-COR Biosciences).
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Appendix A
GENERATION OF A SYNTHETIC NANOBODY LIBRARY
Nanobody is a single domain antibody, with the size around 15 kDa.
Similar to the conventional antibody, nanobody recognizes its epitope using its
complementary determining regions. In contrast to antibody, nanobody is 10
times smaller and readily assembled to functional module in cellulo; hence it has
been widely applied to study numerous protein intracellularly. 1 The engineer of
nanobody could be achieved through either immunization of the camelids, such
as llama or alpaca with the antigen to elicit immune response. The DNA
sequence of the nanobodies were then identified through reverse transcription of
the extracted mRNA from the lymphocytes. The immunized libraries were then
subjected to biopanning, mainly through phage display. On the other hand,
several groups had reported the generation of synthetic nanobody libraries and
successfully isolated nanobody in vitro through directed evolution.2,3 These in
vitro platform is ideal to isolate conformational selective nanobodies and if the
antigen is sensitive to the environment. In addition, the synthetic nanobodies
libraries could be cloned into different display platform, such as yeast display.
The major advantage of yeast display is it could be coupled to fluorescent
activated cell sorting (FACS). The multicolor flow cytometry enables the
normalization of the antigen binding signals with the level of displayed nanobody
and with FACS, each clone could be scrutinized in a high throughput screen.
In this chapter, we demonstrated the preparation and characterization of a
yeast display-based synthetic nanobody library based on an established library
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design.2 We have used the library to isolate nanobodies targeting two
deubiquitinases from distinct families: USP30 and UCH37.
USP30 is a deubiquitinase belongs to the USP family. Studies have
elucidated that USP30 anchors at the outer membrane mitochondria and
antagonizes mitophagy.4 The inhibition of USP30 promotes the clearance of
damaged mitochondria and maybe beneficial for Parkinson’s disease. 5 It is
further demonstrated that mitochondrial damage triggers the ubiquitination of an
atypical Lys6- linked ubiquitin chain on the mitochondrial substrate, which is
hydrolyzed by USP30.6 Structural study of USP30 showed that it has the
preference towards the Lys6-linked ubiquitin chains is through a unique ubiquitin
binding surface.7,8,9 We reasoned that a USP30 nanobody could be used to
probe USP30 spatially and temporally to give insights into the physiological roles
of USP30 in neurological disease. (The generation and characterization of
UCH37 nanobodies are described in Chapter 3 and 4).

Generation of a synthetic Nb library
By adopting the established library design, we displayed our synthetic
nanobody library on the yeast surface with the yeast Aga1p-Aga2p display
system.2 Our ensemble of nanobodies consist similar thorough randomization at
the CDRs and partial randomization at the residues adjacent to the CDRs. The
randomization sites are: (i) residues 27-33, (ii) residues 50-58 and (iii) residues
94-100 according to the Chothia numbering.10,11 Here, the partial randomizations
are achieved through degenerate codons, while the full randomizations are
attained by the utilization of NNK codons, which code for all twenty amino acids
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and one stop codon. We acknowledged that the usage of NNK codons will
introduce Cys with undesired chemical property into our nanobody library. At the
same time, there is a 5% risk to come across a stop codon in the sequence
which lead to the generation of a non-functional truncated nanobody.
Nonetheless, we proceeded with the NNK codons from an economic standpoint.
Nanobody is characterized with its long CDR3 with variable length. 12,13,14
Studies have shown that the diversities of the CDR3 are crucial in distinguishing
the target antigens, and their different lengths determine the binding modes and
the theoretical sequence space of the nanobodies. 15,3,16 Here, similar to the
established nanobody library, we introduced 3 length variations at the CDR3,
with 8, 10, and 13 amino acid residues (according to the Chontia numbering).
Studies have shown that CDR3 with short length, such as 8 and 10 residues
mainly adopts a concave interaction surface, and CDR3 with medium length, for
example, 13 amino acids will offer an extensive loop interaction surface. While
longer CDR3, with more than 17 residues and binds with convex surface, is not
considered in our library design, as the probability of encountering stop codon
would be too high.
The nanobody library is incorporated into the yeast surface display vector with N
terminus Aga2p protein and is flanked between a HA tag and c-Myc tag (Figure
A-1A). Upon transformation, we obtained around 7 x 10 7 transformants. The
utilization of NNK codons would result in 40-50% of truncated nanobodies; we
have performed flow cytometry analysis of the induced library, using the anti-HA
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and anti-cMyc and confirmed the percentage of the full length nanobodies were
44% of the expressed nanobodies (Figure A-1B).

Figure A-1: Yeast display of the synthetic nanobody library.
(A) Scheme of the displayed nanobody library on the yeast surface. (B) Flow
cytometry dot plots of the induced nanobody library. The displayed nanobodies
are either detected with the labeling at the HA tag fused to the N terminus of
nanobody to identify the degree of induction (Left) or detected with the labeling at
the cMyc tag fused to the C terminus of nanobody to determine the degree of the
expression of full length nanobody (Right).

We further validated the quality of the library using next generation
sequencing (NGS). Here, we used the Illumina’s MiSeq paired-end sequencing
(2 x 250 bps) which covers the entire nanobody. We recognized that the capacity
of our MiSeq run is 1 million read at maximum, which is below the size of our
library and the characterization of each clone could not be achieved.
Nonetheless, the sampling depth using NGS is significantly higher than the
traditional Sanger sequencing and could offer a more accurate assessment of
the library diversity.17 From our MiSeq sequencing, among 608168 reads, 33% of
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the clones were in frame. 73% of the in-frame ensembles did not contain any
stop codon with 93% of the full length nanobodies were distinct (clones with
unique sequence) (Table A-1). Thereby, the diversity of our nanobody library is
estimated to be around 2 x 107 distinct clones. A closer inspection of the full
length nanobodies showed that the ratio of the nanobodies with 8, 10, and 13
CDR3 amino acid residues are 3:2:1 (Figure A-2). In addition, we interrogated
the diversities of the amino acids at the CDR loops and our observed frequencies
resembled the theoretical frequencies, suggesting the unbiased incorporation of
the degenerate codons (Figure A-3)
.
Table A-1: Overview of sequencing data of nanobody library
DESCRIPTION
RAW
IN FRAME
FULL LENGTH
UNIQUE

NO. OF
READS
608168
201453
146231
136349

PERCENTAGE
(%)
100.0
33.1
24.0
22.4

RELATIVE
PERCENTAGE (%)
100.0
33.1
72.6
93.2

Raw data represents the total number of merged reads with low quality data
removed; in frame is the number of reads containing in frame nanobody
framework; the number of reads of full length is determined after removing the
nanobody containing at least one stop codon; and unique read is the number of
nanobody with unique sequence. The percentage is calculated based on the
number of reads compare to the raw data while the relative percentage is based
on the percentage relative to previous sub-sampled reads.
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Figure A-2: NGS Analysis of the
length of nanobodies library
Barplot showing the distribution of the
ensemble of nanobodies based on
their length.

Figure A-3: Side by side comparison of the theoretical and observed amino
acid percentage of the nanobody library focusing at CDRs.
The amino acid percentage of the CDR1 (Left) and CDR2 (Middle) of the full
length nanobodies were calculated. As the nanobodies library consist of
members with different CDR3 length, only the ensembles with 8 amino acid
residues at CDR3 (Right) was used in this analysis.
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Generation of the USP30 Nbs
We reasoned that a nanobody which probe intracellular USP30 would
provide information of the functional role of USP30 in a cellular context. Our
preliminary screening against ubiquitin conjugated to USP30 had enriched three
different low affinity nanobody clones towards USP30, as suggested from the
flow cytometry assay (Figure A-4A and B). Especially one nanobody, NbBI.1
showed inhibitory effect on the Lys6 linked- ubiquitin chain hydrolysis activity of
USP30 (Figure A-4C). Affinity maturation is currently in the progress to improve
the binding parameters of these nanobodies.

Figure A-4: Isolating nanobodies for USP30.
(A) Amino acid sequences of the enriched nanobodies for USP30. The
diversified residues in the CDRs are highlighted in colored box. (B) Flow
cytometry plots showing bindings of yeast displayed- nanobodies towards 316
nM USP30. (C) Lys6 linked-ubiquitin chain cleavage assay by USP30 in the
presence of NbBI.1 in a concentration gradient.
The capability to isolate of nanobodies for different antigens suggested
that this nanobody library is robust. We recognized that the main limitation of our
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library is the existence of stop codon due to the usage of NNK codon as a
method to introduce full randomization. This had inevitably led to the generation
of truncated nanobody; it also prevented us from preparing nanobody ensembles
with longer CDR3 to reduce the probability of encountering stop codon in that
region. Usage of the oligos with trimer phosphoramidites would circumvent this
issue.18
Materials and Methods
Cell culture
For yeast cells used in the yeast surface display, referred to the cell culture
section in the Material and Methods in Chapter 2.

Plasmid and Cloning
His6-SUMO-USP3067-517 in pOPINS vector was cloned from Flag-HA-USP30,
which was a gift from Wade Harper (Addgene plasmid # 22578). All PCR
amplifications were performed with Phusion® High-Fidelity DNA polymerase
(New England Biolabs). The primers used in this study were purchased from IDT
DNA. All the sequences were verified through Sanger sequencing.
For bacterial expression of the nanobody, the enriched nanobodies in the
selections were cloned into pET28b (Novagen) through megaprimer PCR.

Construction of a synthetic Nanobody (Nb) library
Our Nb library design is based on published synthetic Nb library and is displayed
through the conventional yeast surface display platform. 2,16,19 The Nb library was
149

constructed by overlapping extension PCR of five oligonucleotides which
composed the framework structure (oligonucleotides a and e) and randomized
regions (oligonucleotides b, c, and dshort/ dmedium/ dlong, and e) of Nb (Table I-2).
The oligonucleotides were generated by performing PCR using a1_f+a2_r,
b3_f+b4_r, c5_f+c6_6, d7_f+d8_short_r/ medium_r/ long_r, and e9_f+e10_r. The
resulting mixture (oligonucleotides a, b, c, d, and e) were mixed at equal ratio for
the following overlapping extension PCR; among them, oligonucleotides d were
further composed of dshort, dmedium, and dlong mixed at a ratio of 1:1:2. Both PCR
were performed using Phusion® high fidelity DNA polymerase (New England
Biolabs) and the conditions were initial denaturation at 98 oC for 30 s, followed by
25 cycles of 98oC for 10 s, 60oC for 30 s, 72oC for 30 s, with a final extension at
72oC for 5 mins. The combined Nb gene library pool was further amplified using
pCT_nb_PstI_f and pCT_nb_BamHI_r.(Table I-2) To generate Nb library, a yeast
surface display vector containing nanobody, pCT_NbNO1 was first generated by
inserting the amplified Nb gene into the plasmid at NheI and BamHI (New
England Biolabs) restriction site. It was followed by transforming the yeast cells
using 1 µg of the Bpu10I and BamHI (New England Biolabs) digested
pCT_NbNO1 plasmid and 5 µg of the amplified Nb gene library pool through
electroporation. The cells were recovered and the size of the transformants was
estimated through the aforementioned procedure. The diversity of the Nb library
was further validated through next generation sequencing (Refer to Material and
Method section in Chapter 3 for NGS library sample preparation and analysis).
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Table A-2: Primers used in the generation of the nanobody library
Primers

Sequence (5'-3')

GCTAGCCAGGTGCAGCTGCAGGAAAGCGGCGGCGG
CCTGGTGCAGGCGGGC
GCCGCTCGCCGCGCAGCTCAGGCGCAGGCTGCCGC
a2_r
CCGCCTGCAC
CGCGGCGAGCGGCWMTATTTYTNNKNNKNNKNNKA
b3_f
TGGGCTGGTAT
AATAGYAGCAACAAGTTCGCGTTCTTTGCCCGGCGC
b4_r
CTGGCGATACCAGCCCAT
GTTGCTRCTATTRVTNNKGGTRSTANTACCWATTATG
c5_f
CGGATAGCGTGAAAGGCCGCTTT
TTCATCTGCAGATACACGGTGTTTTTCGCGTTATCGC
c6_r
GGCTAATGGTAAAGCGGCCTTT
TCTGCAGATGAACAGCCTGAAACCGGAAGATACCGC
d7_f
GGTGTATTATTGCGCGG
CCCCAATATGCAWRMNNMNNMNNMNNMNNARCCG
d8_short_r
CGCAATAAT
CCCCAATATGCAWRMNNMNNMNNMNNMNNMNNMN
d8_medium_r
NARCCGCGCAATAAT
CCCCAATATGCAWRMNNMNNMNNMNNMNNMNNMN
d8_long_r
NMNNMNNMNNARCCGCGCAATAAT
GCATATTGGGGCCAGGGCACCCAGGTGACCGTGAG
e9_f
CAGCGGTGGTGGTGGTAGC
GTCCCCGAAGTTCAGACCGGTGCTACCACCACCACC
e10_r
GCTGCTCACGGT
pCT_nb_PstI_f
GGTGGTGGTTCTGCTAGCCAGGTGCAGCTGCAGGAA
TTACAAGTCCTCTTCAGAAATAAGCTTTTGTTCGGATC
pCT_nb_BamHI_r
CGCTACCACCACCGCT
Codons used for partial and full randomization are highlighted in bold.
a1_f

Protein purification
All protein purifications were performed at 4oC.
Avi-USP3067-517/USP3067-517 were purified through nickel (Gold Biotechnology)
affinity chromatography. In brief, the USP30 construct were expressed in E. coli
Rosetta (DE3) pLysS. The cells were grown at 37 oC to OD 0.5 before induced
with 0.1 mM IPTG at 20oC overnight. The cells were lysed in 50 mM Tris, pH 8,
300 mM NaCl, 10 mM imidazole and subjected to nickel resin to pull down the
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His8-SUMO-USP30 construct. The protein was eluted with 50 mM Tris, pH 8, 150
mM NaCl, 300 mM imidazole, followed by ULP1 cleavage reaction in 50 mM Tris,
pH 8, 150 mM NaCl, 1 mM TCEP to remove the His8-SUMO tag. The protein was
further purified through size exclusion chromatography on a HiLoad Superdex 75
pg on an ÄKTA purifier (GE Healthcare). The running buffer was 50 mM Tris, pH
7.5, 300 mM NaCl, 1 mM TCEP. For the preparation of the biotinylated Ub
conjugated to USP3067-517, biotinylated USP3067-517, and His6-nanobody, refer to
the Material and Method section in Chapter 3.
To prepare K6-linked ubiquitin chain, 0.5 mM Ub K48R (referred to protein
expression and purification section in the Materials and Methods in Chapter 2 for
ubiquitin K48R purification) was reacted with 0.2 µM E1, 2 µM UbcH5c, 0.5 µM
MleL in a buffered solution containing 40 mM Tris, 10 mM MgCl 2, 10 mM ATP,
and 0.2 mM DTT at pH 7.5 for 37oC overnight. The reactions were quenched
using 10 mM DTT in 50 mM NH4OAc, pH4.4 solution for at least 30 min before
purified using size exclusion chromatography using a HiLoad Superdex 75 pg on
an ÄKTA purifier (GE Healthcare). The running buffer was 50 mM Tris, pH 7.5,
300 mM NaCl, 1 mM DTT.

Selection of Nanobodies (Nbs) against USP30 67-517
Briefly, the induced Nb library were subjected to two rounds of magnetic
activated cell sorting (MACS) using biotinylated Ub conjugated to USP30 67-517
and followed by two rounds of fluorescent activated cell soritng (FACS) using
either biotinylated Ub conjugated to USP30 67-517 or biotinylated USP3067-517 as
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antigen. Refer to Material and Method section for the preparation of the yeast
cells for sorting.

Validation of the enriched mutations
Yeast cells were transformed with the plasmid encoded for the nanobodies with
enriched mutations (referred to Yeast growth and induction in the Materials and
Methods in Chapter 2). The yeast cells were cultured, induced, and washed as
previously described. For validation, the cells were incubated with the
biotinylated USP3067-517 in PBS for 30 mins, at room temperature with gentle
rocking. The cells were then similarly labeled with primary and secondary
antibodies as mentioned in the Selection of nanobodies against USP30 67-517
before subjected to flow cytometry analysis on a BD LSR Fortessa X20.

USP30 activity assay
1 µM USP30 was pre-incubated with nanobody at a concentration gradient in a
buffered solution of 50 mM HEPES, pH 7.5, 50 mM NaCl, 3 mM DTT before
reacted with 0.3 mg/ml high molecular weight Lys6- linked ubiquitin chains for 30
mins at 37oC. The activity of USP30 in the presence of nanobody was accessed
by gel densitometry. Gels were stained with SYPRO TM Ruby and scanned on a
Typhoon FLA 9500 (GE Healthcare). Data analysis was performed on Image
Studio Lite (LI-COR Biosciences).
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Appendix B
SUPPLEMENTARY FIGURES AND TABLES

Figure B-1: Auto-ubiquitination of Yuh1 variants
Representative SDS PAGE analysis showing the whole gel of the
autoubiquitination of (A) Yuh1qm, (B) Yuh1qm3.1, (C) Yuh1qm5.1, (D)
Yuh1qm5.3 and (E) Yuh1qm5.6 with monoubiquitin.
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Figure B-2: Profiling USP activities towards anchored and free ubiquitin
chains
Free and anchored (A) K48 Ub2 and (B) K63 Ub2 cleavage assay by USP11,
USP15 and USP21 with plots showing the disappearance of anchored (or free)
ubiquitin dimer and the formation anchored (or free) mono-ubiquitin. Error bars
corresponded to standard error of three biological replicates.
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Figure B-3: Alternative anchored Lys48 linked ubiquitin dimer cleavage
assay
(A) Non-NEM treated anchored Lys48 linked ubiquitin dimer cleavage assay by
USP15. (B) Anchored and free Lys48 linked ubiquitin dimer cleavage assay by
OTUB1-UBE2D2 (OTUB1*).

Table B-1: Primers used in the reprogramming of Yuh1
Primer
pCT-yuh1_f
pCT-yuh1_r
pCT-yuh1_f2
pCT-yuh1_r2

Sequencing (5’-3’)
GGTGGTTCTGCTAGCATGTCGGGTGAAAAC
CTTTTGTTCGGATCCTTCCCAGTTCGGGCC
GACAATAGCTCGACGATTGAAGGTAGATACCCATACGA
CGTTCCAGACTAC
ATCAGATCTCGAGCTATTACAAGTCCTCTTCAGAAATAA
GCT
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Figure B-4: Titration curve of yeast displayed nanobody with
UCH37∙RPN13DEU
Flow cytometry histograms of yeast displayed NbAI.1 (Left), NbAII.1 (Middle) and
NbAII.2 (Right) incubated with biotinylated UCH37∙RPN13 DEU. Cells were labeled
with streptavidin conjugated Alexa Fluor® 488.

Figure B-5: Validation of the scheme for the affinity maturation of NbAI.1
Flow cytometry dot plot of yeast cells displaying the ensembles of random
mutagenized NbAI.1 incubated with WT (Left) and UCH37 KO HEK293FT RPN11HTBH (Right). The frame and percentages designate the fraction of yeast cells
showing binding towards the antigen.
159

Figure B-6: Investigation of the enriched mutations
Flow cytometry plots showing the lack of binding of the yeast surface displayednanobodies containing the enriched mutations towards cell lysate generated from
UCH37 KO HEK293RPN11-HTBH. The enriched mutations are highlighted in bold.
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Figure B-7: Specificity assessment of NbAIII.15 through
immunoprecipitation-mass spectrometry (IP-MS)
Plots of peptide spectral matches (PSMs) vs coverage for the proteins identified
with p<0.05 through immunoprecipitation-mass spectrometry. The significance
was compared by Student’s t test between the protein abundance ratio
immunoprecipitated by NbAIII.15 and NbCtrl. Data for UCH37 are highlighted in
pink and proteasome-associated subunits are labeled in blue.

Table B-2: NbAIII.15 fragments identified in the limited proteolysis of
NbAIII.15 in complex with UCH37·RPN13 DEU
Measured Mass Calculated Mass
Observed amino acid residues
[M+H]
[M+H]
2227
2228
64-84
5108
5108
96-141
6828
6828
1-63
7684
7686
1-141
Only proteolysis fragments generated from NbAIII.15 were listed here. These
fragments were detected in two biological replicates. The identities of the
proteolysis fragments were determined using ProteinProspector.
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Table B-3: Primers for the generation of random mutagenized NbAI.1 library
Primers

pCT_Nb_amp_f
pCT_Nb_amp_r

Sequence (5'-3')

GACAATAGCTCGACGATTGAAGGTAGATACCCATACG
ACGTTCCAGACTAC
ATCAGATCTCGAGCTATTACAAGTCCTCTTCAGAAATA
AGCT

Table B-4: Primers used in the preparation of library for next generation
sequencing
Primers

Sequence (5'-3')

TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNGAC
GTTCCAGACTAC
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGNNNCA
Nbseq_deg_r
AGTCCTCTTCAGA
AATGATACGGCGACCACCGAGATCTACACCTCTCTATTCG
Nbseq_N502
TCGGCAGCG
AATGATACGGCGACCACCGAGATCTACACTATCCTCTTCG
Nbseq_N503
TCGGCAGCG
CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTCTCGT
Nbseq_N701
GGGCT
Codons used as the unique identified code are highlighted in bold and codons in
italic represent the index adaptors for multiplex next generation sequencing.
Nbseq_deg_f

Figure B-8: Investigate the effect of
NbAII.1 towards UCH37
Representative gel for the cleavage assay
using high molecular weight Lys6-/ Lys48linked branched ubiquitin chains by UCH37
against a concentration gradient of NbAII.1.
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Figure B-9: Investigate the effect of nanobodies towards UCH37∙RPN13
Representative gel for the cleavage assay using high molecular weight Lys6-/
Lys48- linked branched ubiquitin chains by UCH37∙RPN13 against a
concentration gradient of (A) NbAI.1, (B) NbAII.1, (C) NbAIII.15, and (D)
NbAIII.16.

Figure B-10: Comparison of the
inhibition effect of NbAII.1
towards UCH37 and
UCH37∙RPN13
Comparison of the debranching
activities of UCH37 and
UCH37∙RPN13 treated with
control, NbAI.1 and NbAII.1. Error
bars represent the standard error
of two biological replicates.
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Figure B-11: Purified proteasome-associated
UCH37
Western blots of the purified proteasome-associated
UCH37 validate the presence of UCH37 and absence
of USP14 on the proteasome. Western blot against
RPN11 and 20βS, which are the constitutive subunits
of the 19S RP and 20S CP confirmed the identity of
26S proteasome complex.

Figure B-12: Conditionally stable NbAIII.15 in WT and UCH37 KO HEK293FT
cells
Representative full Western blots showing the protein level (Left) of the
nanobodies in the WT and UCH37 KO HEK293FT cells. β-Actin (Right) was used
as the loading control.
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Figure B-13: Conditionally stable NbAIII.15 in UCH37 KO HEK293FT cells
without and with ectopically expressed UCH37
Representative full Western blots showing the protein level (Left) of the
nanobodies in the UCH37 KO HEK293FT cells without and with overexpressed
UCH37. β-Actin (Right) was used as the loading control.

Figure B-14: Conditionally stable NbCtrl in UCH37 KO HEK293FT cells
without and with ectopically expressed UCH37
(A) Representative Western blot and (B) the expression level (Left) and fold of
induction (Right) of NbCtrl variants in UCH37 KO HEK293FT cells without and
with overexpressed UCH37. Error bars represent the standard error of two
biological replicates.
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